CONTRACEPTIVE COMPOSITIONS CONTAINING QUINAZOLINONE AND BENZOXAZINE DERIVATIVES

Abstract: This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of general structure: (I) wherein: R<1> and R<2> are H, COR<A>, or NR<B>COR<A>, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic; or R<1> and R<2> fuse to form 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; R<A> is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; R<B> is H or alkyl; R<3> is H, OH, NH2, COR<C> or alkyl, alkenyl, or alkynyl; R<C> is H, alkyl, aryl, alkoxy, or aminoalkyl; R<4> is H, halogen, CN, NO2, alkyl, alkynyl, alkoxy, amino or aminoalkyl; R<5> is benzen or 5- or 6-membered heterocyclic ring; R<6> is H or alkyl; G1 is O, NR7, or CR7R8; G2 is CO or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof. These methods may be used for contraception or treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

Description: CONTRACEPTIVE COMPOSITIONS CONTAINING QUINAZOLINONE AND BENZOXAZINE DERIVATIVES Field of the Invention 5 This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both. Background of the Invention Intracellular receptors (IR) form a class of structurally related gene regulators 10 known as "ligand dependent transcription factors" (R. M. Evans, Science, 240, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). The natural hormone, or ligand, for the PR is the steroid progesterone, but 15 synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates 20 the production of mRNA and protein encoded by that gene. A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist. PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in 25 the presence of an ER agonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus that can lead to an increased risk of uterine cancers. Co-administration of a PR agonist reduces or ablates that risk. PR antagonists may also be used in contraception In this context they may be administered alone (Ulmann, et al, Ann N Y Acad Sci , 261, 248, 1995), in combination with a PR agonist (Kekkonen, et al, Fertility and Sterility, 60, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997 Al July 4, 1996) PR antagonists may also be useful for the treatment of hormone dependent breast cancers (Horwitz, et al, Horm Cancer, 283, pub Birkhaeuser, Boston, Mass , ed Vedeckis) as well as uterine and ovarian cancers PR antagonists may also be useful for the treatment of non-malignant chronic conditions such as fibroids (Murphy, et al, J Chn Endo Metab , 76, 513, 1993) and endometπosis (Kettel, et al, Fertility and Sterility, 56, 402, 1991) PR antagonists may also be useful in hormone replacement therapy for post menopausal patients in combination with a partial ER antagonist such as tamoxifen (US 5719136) PR antagomsts, such as mrfepπstone and onapπstone, have been shown to be effective in a model of hormone dependent prostate cancer, which may indicate their utility in the treatment of this condition in men (Michna, et al, Ann N Y Acad Sci , 761, 224, 1995) Jones, et al, (U S Patent No 5,688,810) describe the PR antagonist dihydroquinoline 1 Jones, et al, described the enol ether 2 (U S Patent No 5,693,646) as a PR ligand Jones, et al, descπbed compound 3 (U S Patent No 5,696,127) as a PR ligand Zhi, et al, descπbed lactones 4, 5 and 6 as PR antagomsts (J Med Chem, 41, 291, 1998) Zhi, et al, described the ether 7 as a PR antagonist (J. Med. Chem, 41, 291, 1998). Combs, et al, disclosed the amide 8 as a ligand for the PR (J. Med. Chem., 38, 4880, 1995). 8 Perlman, et. al, described the vitamin D analog 9 as a PR ligand (7et. Letters, 35, 2295, 1994). Hamann, et al, descπbed the PR antagomst 10 (Ann N Y Acad Sci , 761, 383, 1995) 10 Chen, et al, descπbed the PR antagomst 11 (Chen, et al, POI-37, 16 th Int Cong Het Chem , Montana, 1997) 11 Kuπhari, et al , descπbed the PR ligand 12 (J Antibiotics, 50, 360, 1997) 12 A number of publications reported the synthesis and utilities of benzodiazinones and benzoxazmes Included in this literature is the patent by Kubla et al (US 4666913) which claimed that the compound such as A and B could be used as cardiotonic agents Ning et al reported the synthesis of quinazo nones such as C Gromachevskaya et al (Chem Heterocycl Compd (N Y ), 33(10), 1209-1214 (1998)) studied the bromination process of certain benzoxazmes such as compound D Kobzina et al (U S Patent No 3,917,592) claimed that compounds such as E can be used as a herbicidal agent Pflegel et al (Pharmazie, 37(10), 714-717(1982)) disclosed quιnazolιn-2- thiones such as compound F in their study of polarography of heterocychcs No activity of the compound F was mentioned U S Patent No 5,521,166 (Grubb) teaches cyclophasic hormonal regimens compπsing an antiprogestin and a progestin wherein the progestin is administered in the alternating presence and absence of an antiprogestin The disclosed regunens also provide for use of an estrogen for a peπod of from 2-4 days to prevent breakthrough bleeding Description of the Invention This invention provides combination therapies and dosing regimens utilizing antiprogestational agents in combination with one or more progestational agents This invention further provides methods of treatment and dosing regunens further utilizing in combination with these antφrogestins and progestrns, an estrogen, such as ethinyl estradiol These regimens and combinations may be administered to a mammal to induce contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometπosis, polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometπum, ovary, breast, colon, prostate Additional uses of the invention include stimulation of food intake The uses herein for the treatment and/or prevention of the conditions or diseases descπbed above includes the continuous administration or peπodic discontinuation of administration of the invention to allow for minimization of effect dose or minimization of side effects or cyclic menstrual bleeding The use of this invention for contraception includes administration, preferably orally, to a female of child bearing age an antiprogestin in combination with an estrogen or progestin or both These administration regimens are preferably earned out over 28 consecutive days, with a terminal portion of the cycle containing administration of no progestrns, estrogens or anti-progestins The progestrns of these combinations may be administered alone or in combination with an estrogen for the first 14-24 days of the cycle, the progestrns being administered at a dosage range equal in progestational activity to about 35 μg to about 150 μg levonorgestrel per day, preferably equal in activity to from about 35 μg to about 100 μg levonorgestrel per day An antiprogestin may then be admimstered alone or in combmation with an estrogen for a peπod of 1 to 11 days to begin on any cycle day between day 14 and 24 The anti-pro gestin in these combinations may be admimstered at a dose of from about 2μg to about 50 μg per day and the estrogen may be admimstered at a dose of from about 10 μg to about 35 μg per day In an oral administration, a package or kit containing 28 tablets will include a placebo tablet on those days when the antiprogestin or progestin or estrogen is not admimstered In a preferred embodiment of this invention, the progestrns of this invention may be admimstered alone or m combination with estrogen for the initial 18 to 21 days of a 28-day cycle, followed by administration of an antiprogestin, alone or in combmation with an estrogen, for from 1 to 7 days The estrogen to be used in the combinations and formulations of this invention is preferably ethinyl estradiol Progestational agents useful with this invention include, but are not limited to, levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethrndrone, gestodene, norethindrone acetate, norgestimate, osaterone, cyproterone acetate, tπmegestone, dienogest, drospirenone, nomegestrol, or (17-deacetyl)norgestιmate Among the preferred progestrns for use in the combinations of this invention are levonorgestrel, gestodene and tπmegestone Examples of orally administered regimens of this invention over a 28 day cycle include administration of a progestational agent solely for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 100 μg of levonorgestrel An antiprogestin compound of this mvention may then be admimstered at a daily dose of from about 2 to 50 mg from day 22 to day 24, followed by no administration or administration of a placebo for days 25 to 28 It is most preferred that the daily dosages of each relevant active ingredient be incorporated into a combmed, single daily dosage unit, totaling 28 daily units per 28-day cycle In another regimen, a progestational agent may be coadministered for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, with an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 μg. This may be followed as described above with an antiprogestin administered at a daily dose of from about 2 to 50 mg from day 22 to day 24, followed by no administration or administration of a placebo for days 25 to 28. Still another regimen within the scope of this invention will include coadministration from days 1 to 21 of a progestational agent, the progestational agent, preferably levonorgestrel, being administered at a daily dose equal in progestational activity to from about 35 to about 100 μg levonorgestrel, and an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 μg. This will be followed on days 22 to 24 by coadmi-nistration of an antiprogestin (2 to 50 mg/day) and an estrogen, such as ethinyl estradiol, at a daily dose of from about 10 to about 35 μg. From day 25 to day 28, this regimen may be followed by no aclministration or administration of a placebo. This invention also kits or packages of pharmaceutical formulations designed for use in the regimens described herein. These kits are preferably designed for daily oral administration over a 28-day cycle, preferably for one oral administration per day, and organized so as to indicate a single oral formulation or combination of oral formulations to be taken on each day of the 28-day cycle. Preferably each kit will include oral tablets to be taken on each the days specified, preferably one oral tablet will contain each of the combined daily dosages indicated. According to the regimens described above, one 28-day kit may comprise: a) an initial phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in progestational activity to about 35 to about 100 μg levonorgestrel; b) a second phase of from 1 to 11 daily dosage units of an antiprogestm compound of this mvention, each daily dosage umt containmg an antiprogestm compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of an orally and pharmaceutically acceptable placebo for the remammg days of the cycle m which no antiprogestm, progestm or estrogen is admimstered A preferred embodiment of this kit may compπse a) an initial phase of 21 daily dosage units of a progestational agent equal m progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal m progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestm compound of this mvention, each daily dosage umt containmg an antiprogestm compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28 Another 28-day cycle packagmg regimen or kit of this mvention compπses a) a first phase of from 18 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal m activity to from about 35 to about 100 μg levonorgestrel, and, as an estrogen, ethmyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestm of this mvention at a daily dose of from about 2 to 50 mg, and c) optionally, an orally and pharmaceutically acceptable placebo for each of the remammg 0-9 days m the 28-day cycle m which no progestational agent, estrogen or antiprogestm is admimstered A preferred embodiment of the kit descπbed above may compπse a) a first phase of 21 daily dosage units of a progestational agent equal m progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, and, as an estrogen, ethinyl estradiol at a daily dose range of from about 10 to about 35 μg; and b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestin administered at a daily dose of from about 2 to 50 mg; and c) optionally, a third phase of 4 daily dose units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28. A further 28-day packaged regimen or kit of this invention comprises: a) a first phase of from 18 to 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably equal in activity to from about 35 to about 100 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg; b) a second phase of from 1 to 7 daily dose units, each daily dose unit containing an antiprogestin of this invention at a concentration of from 2 to 50 mg; and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) optionally, an orally and pharmaceutically acceptable placebo for each of the remaining 0-9 days in the 28-day cycle in which no progestational agent, estrogen or antiprogestin is administered. A preferred embodiment of the package or kit just described comprises: a) a first phase of 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 μg levonorgestrel, preferably from about 35 to about 100 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg; b) a second phase of 3 daily dose units for days 22 to 24, each dose unit containing an antiprogestin of this invention at a concentration of from 2 to 50 mg; and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28. In each of the regimens and kits just descπbed, it is preferred that the daily dosage of each pharmaceutically active component of the regimen remain fixed m each particular phase m which it is admimstered It is also understood that the daily dose units descπbed are to be admimstered m the order descπbed, with the first phase followed m order by the second and third phases To help facilitate compliance with each regimen, it is also preferred that the kits contain the placebo descπbed for the final days of the cycle It is further preferred that each package or kit compπse a pharmaceutically acceptable package having indicators for each day of the 28-day cycle, such as a labeled blister package or dial dispenser packages known m the art In this disclosure, the terms anti-progestational agents, anti-progestins and progesterone receptor antagomsts are understood to be synonymous Similarly, progestrns, progestational agents and progesterone receptor agonists are understood to refer to compounds of the same activity These dosage regimens may be adjusted to provide the optimal therapeutic response For example, several divided doses of each component may be admimstered daily or the dose may be proportionally mcreased or reduced as indicated by the exigencies of the therapeutic situation In the descπptions herein, reference to a daily dosage unit may also mclude divided units which are admimstered over the course of each day of the cycle contemplated Compounds of this mvention which may be used as the anti-progestational agents m the kits, methods and regunens herem are those of the Formula I wherem R 1 , R 2 are independent substituents selected from the group which includes H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR A , or NR B COR A ; or R 1 and R 2 are fused to form: a) an optionally substituted 3 to 8 membered spirocyclic alkyl ring; b) an optionally substituted 3 to 8 membered spirocyclic alkenyl; or c) an optionally substituted 3 to 8 membered heterocyclic ring containing one to three heteroatoms from the group including O, S and N; the spirocyclic rings of a), b) and c) being optionally substituted by from 1 to 4 groups selected from fluorine, Ci to C 6 alkyl, Ci to C 6 alkoxy, to C 6 thioalkyl, -CF 3 , -OH, - CN, NH 2 , -NH(C, to C 6 alkyl), or -N(C, to C 6 alkyl) 2 ; R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, substituted C, to C 3 alkyl, R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted G to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, COR c , R c is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, R 4 is H, halogen, CN, N0 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, alkynyl, or substituted alkynyl, Ci to Cβ alkoxy, substituted Ci to Cβ alkoxy, amino, Ci to C 6 aminoalkyl, substituted Ci to C 6 aminoalkyl, R 5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below, X is taken from the group mcludmg halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, alkynyl, or substituted alkynyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C thioalkoxy, substituted Ci to C 3 thioalkoxy, ammo, Ci to C 3 ammoalkyl, substituted Ci to C 3 ammoalkyl, N0 2 , Ci to C 3 perfluoro alkyl, 5 or 6 membered heterocyclic πng containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, G to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 ammoalkyl, R E is H, Ci to C 3 alkyl, substituted G to C 3 alkyl, Y and Z are mdependent substituents taken from the group mcludmg H, halogen, CN, N0 2 , ammo, ammoalkyl, Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy, or R 5 is a five or six membered πng with 1, 2, or 3 heteroatoms from the group mcludmg O, S, SO, S0 2 or NR 6 and containmg one or two mdependent substituents from the group mcludmg H, halogen, CN, NO 2 amino, and Ci to C 3 alkyl, G to C 3 alkoxy, Ci to C 3 ammoalkyl, COR F , or NR G COR F , R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 ammoalkyl, R G is H, Ci to C 3 alkyl, or substituted C, to C 3 alkyl, R 6 is H or C, to C 3 alkyl, provided that when Gi is O, G 2 is CR 7 Rs, and Gi and G 2 cannot both be CR 7 Rs; R 7 and R 8 are independent substituents selected from H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof. Preferred antiprogestin compounds of this invention include those of Formula I: I wherein: R 1 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR A , or NR B COR A ; R 2 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C. alkenyl, substituted C 2 to C 6 alkenyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR A , or NR B COR A ; or R 1 and R 2 are fused to form an optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring containing one to three heteroatoms from the group including O, S and N, as described above; R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl; R B is H, Ci to C 3 alkyl, or substituted G to C 3 alkyl, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, COR c , R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted aryl, Ci to C alkoxy, substituted Ci to C alkoxy, Ci to C ammoalkyl, or substituted Ci to C ammoalkyl, R 4 is H, halogen, CN, N0 2 , Q to C 6 alkyl, substituted Ci to C 6 alkyl, Ci to C 6 alkoxy, substituted Ci to C 6 alkoxy, ammo, Ci to C 6 ammoalkyl, substituted Ci to C 6 ammoalkyl, R 5 is a tπsubstituted benzene πng contammg the substituents X, Y and Z as shown below X is selected from halogen, CN, Ci to C 3 alkyl, substituted G to C 3 alkyl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, ammo, Ci to C3 ammoalkyl, substituted Ci to C 3 ammoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocyclic πng contammg 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 ammoalkyl, R E is H, Ci to C 3 alkyl, or substituted G to C 3 alkyl, Y and Z are mdependent substituents taken from the group mcludmg H, halogen, CN, N0 2 , Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy, or R 5 is a five or six membered rmg with 1, 2, or 3 heteroatoms from the group mcludmg O, S, SO, S0 2 or NR 6 and contammg one or two mdependent substituents from the group mcludmg H, halogen, CN, N0 2 ammo, and Ci to C 3 alkyl, Ci to C 3 alkoxy, R 6 is H, or Ci to C 3 alkyl G 2 is CO or CR 7 Rs , with the proviso that when Gi is O, G 2 is CR 7 Rg, and Gi and G 2 cannot both be CR 7 Rs, wherem R 7 and Rs are mdependent substituent selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic or a pharmaceutically acceptable salt thereof Still, more prefened antiprogestm compounds mclude those of the formula I wherem R 1 = R 2 and are selected from G to C 3 alkyl, substituted G to C 3 alkyl, or spirocyclic alkyl constructed by fusmg R 1 and R 2 to form a 3 to 6 membered spirocyclic πng, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted C, to C 6 alkyl, -COH, -CO(Cι to C 4 alkyl) or-CO(Cι to C 4 alkoxy), R 4 is H, halogen, N0 2 , C, to C 3 alkyl, substituted G to C 3 alkyl, R 5 is a disubstituted benzene ring contammg the substituents X, and Y as shown below X is taken from the group mcludmg halogen, CN, Ci to C 3 alkoxy, Ci to C 3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocyclic πng contammg 1 to 3 heteroatoms, Ci to C 3 thioalkoxy, Y is a substituent on the 4' or 5' position from the group mcludmg H, halogen, CN, N0 2 , C, to C 3 alkoxy, G to C 4 alkyl, C, to C 3 thioalkoxy or R 5 is a five membered rmg with the structure shown below R 6 is H, or Ci to C 3 alkyl, C, to C 4 C0 2 alkyl, X' is from the group mcludmg halogen, CN, N0 2 , Ci to C 3 alkyl and Ci to C 3 alkoxy Y' is from the group mcludmg H and Ci to C 4 alkyl or R is a six membered πng with the structure shown X 1 is N or CX 2 , X 2 is halogen, CN, alkoxy, or N0 2 G 2 is CO or CR 7 Rs provided that when Gi is O, G 2 is CR 7 Rs, and Gi and G 2 cannot both be CR 7 Rs; wherein R 7 and Re are independent substituents selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic; or pharmaceutically acceptable salt thereof Still, other preferred antiprogestin compounds are those of Formula I I wherein: R 1 = R 2 and are selected from the group which includes CH 3 and spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 6 membered spirocyclic ring, R 3 is H, OH, NH 2 , CH 3 , substituted methyl, COR c , R c is H, Cj to C 3 alkyl, G to C 4 alkoxy, R 4 is H, halogen, Ci to C 3 alkyl, R 5 is a disubstituted benzene ring containing the substituents X, and Y as shown below X is taken from the group including halogen, CN, methoxy, N0 2 , 2-thiazole, Y is a substituent on the 4' or 5' position from the group including H and F, or R 5 is a five membered ring with the structure shown below X' is from the group mcludmg halogen, CN, N0 2 , Y' is from the group mcludmg H and Ci to C alkyl provided that when Gi is O, G 2 is CR 7 R g , and Gi and G 2 cannot both be CR 7 Rs, R 7 and R 8 are mdependent substituent selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic, and pharmaceutically acceptable salts thereof The antiprogestm compounds of this mvention may contain an asymmetric carbon atom and some of the compounds of this mvention may contain one or more asymmetπc centers and may thus give πse to optical isomers and diastereomers While shown without respect to stereochemistry m Formula I, the present mvention mcludes such optical isomers and diastereomers, as well as the racemic and resolved, enantiomeπcally pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof It will be understood by one skilled m the art that the number of substituents listed for spirocyclic or heterospirocyclic rings formed by fusmg Ri and R 2 will be determmed by the size of the spirocyclic πng The term "alkyl" is used herem to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups havmg one to eight carbon atoms, "alkenyl" is intended to include both straight- and branched-chain alkyl group with at least one carbon-carbon double bond and two to eight carbon atoms, "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least one carbon-carbon triple bond and two to eight carbon atoms The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just descπbed having one or more substituents from the group mcludmg halogen, CN, OH, N0 2 , ammo, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety The term "aryl" is used herem to refer to an aromatic system which may be a smgle πng or multiple aromatic rmgs fused or linked together as such that at least one part of the fused or linked rmgs forms the conjugated aromatic system The aryl groups mclude but not limited to phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl The term "substituted aryl" refers to aryl as just defined having one to four substituents from the group mcludmg halogen, CN, OH, N0 2 , ammo, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio The term "heterocyclic" is used herem to descπbe a stable 4- to 7-membered monocychc or a stable multicychc heterocyclic πng which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group mcludmg N, O, and S atoms The N and S atoms may be oxidized The heterocyclic rmg also mcludes any multicychc πng m which any of above defined heterocyclic rmgs is fused to an aryl πng The heterocyclic πng may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable Such heterocyclic groups mclude, for example, tetrahydrofuran, pipeπdmyl, piperazmyl, 2-oxopιpeπdιnyl, azepmyl, pyrrohdmyl, imidazolyl, pyridyl, pyrazinyl, pyπmidmyl, pyπdazmyl, oxazolyl, isoxazolyl, morpholmyl, indolyl, quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholmyl, thiamorphohnyl sulfoxide, and lsoquinolinyl The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having one to four substituents selected from the group which includes halogen, CN, OH, N0 2 , amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio. The term "alkoxy" refers to the OR group, where R is alkyl or substituted alkyl. The term "aryloxy" is used herein to indicate the OR group, where R is aryl or substituted aryl. The term "alkylcarbonyl" refers to the RCO group, where R is alkyl or substituted alkyl. The term "alkylcarboxy" refers to the COOR group, where R is alkyl or substituted alkyl. The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups, containing one to eight carbon atoms, which may be either same or different and the point of attachment is on the nitrogen atom The term "halogen" refers to CI, Br, F, and I element. The antiprogestin compounds of this invention can be prepared following the Schemes illustrated below: Scheme I ArB(OH) 2 , Pd(Ph 3 P) , Na 2 C0 3 DME H 2 O, N 2 , 85 degrees C p-TSA, toulene As demonstrated in Scheme I, the anti-progestational compounds of this mvention are generally prepared by employmg the suitable couplmg reaction as a key step An appropπately substituted ortho-ammo benzoic acid or its deπvatives such as ethyl ester (X = Br, I, CI, or a latent couplmg precursor such as alkoxy group which can be converted mto OTf group suitable m the couplmg reaction ) was treated with a suitable organo metallic reagent, e g Gπgnard reagent, m appropπate nonprotic solvents which mclude but not limited to THF or ether to give ortho-amino carbinol 2 under an inert atmosphere such as argon or mtrogen at -78 °C to room temperature The arylation of ammo carbinol 2 to yield 3 can be effected by various couplmg reactions including Suzuki, Stille reactions These reactions are commonly performed m the presence of a transition metallic catalyst, e g , palladium or mckel complex often with phosphino hgands, e g , Ph 3 P, dppf, dppe or a catalyst such as palladium acetate Under this catalytic condition, an appropπately substituted nucleophihc reagent, e g , aryl boromc acid, arylstarmane, or aryl zmc compound, is coupled with ammo carbinol 2 to give 3 If a base is needed m the reaction, the commonly used bases mclude but not limited to sodium bicarbonate, sodium carbonate, potassium phosphate, baπum carbonate, cesium fluoπde, or potassium acetate The most commonly used solvents in these reactions mclude benzene, DMF, isopropanol, ethanol, DME, ether, acetone, or a mixture of above solvent and water The couplmg reaction is generally executed under an mert atmosphere such as mtrogen or argon at temperatures ranging from room temperature to 95 °C The compounds of this invention 4 can be effected by treatment of ammo carbinol 3 with an appropπate ketone m the presence of an suitable acid catalyst such as -toluenesulfbnic acid m a suitable solvent such as toluene, benzene under an mert atmosphere such as argon or nitrogen at room temperature to reflux Scheme II descπbes the procedure to prepare benzoxazmes bearing two different substituents at posιtιon-4 The Weinreb amide 6 can be prepared from an appropπately substituted isatoic anhydπde 5 when treated with N-, O- drniethylhydroxyl-amme hydrochloπde salt m a protic solvent such as ethanol, or isopropanol at reflux under an mert atmosphere such as argon or mtrogen Couplmg of amide 6 with an aryl electrophile such as aryl boromc acid or arylstannane to give 7 can be effected by employing a typical couplmg reaction such as Suzuki, Stille coupling procedure m a similar fashion as described for the preparation of compound 3 Treatment of Weinreb amide 7 with organo metallic compounds, e g , alkylhthium, alkynylhthiu , aryllithium, or their Gπgnard counterpart m a nonprotic solvent such as THF or ether under an mert atmosphere such as argon or mtrogen at -78 ° to room temperature affords ammo ketone 8 Conversion of ketone 8 to carbinol 9 can be effected by treatment of 8 with an organo metallic reagent such as alkyl, alkynyl, or aryl Gπgnard reagent m a nonprotic solvent such as THF or ether under an mert atmosphere such as argon or mtrogen at -78 °C to room temperature Conversion of ketone 8 to carbinol 9 can also be effected by reduction of ketone group of 8 to the carbinol moiety of 9 using an appropriate reducing reagent such as hthium aluminum hydride, sodium borohydride in a suitable solvent such as THF, ether, or anhydrous alcohol under an inert atmosphere in the temperature ranging from 0 °C to the boiling point of the solvent. Further conversion of 9 to the compounds of this invention can be effected as described in scheme I for the preparation of compound 4. Scheme II EtOH, NHO eMe, HC1, reflux ArB(OH) 2 , PάχPh,P) , Na 2 CO, DME/H 2 0, 85 degrees C, N 2 Rg l or ---6-VlgX, THF, -78 degrees C to it Ry gX, -78 degrees C to it, N 2 or reducing agent Alternatively, ortho-amino ketone 8 can be prepared by treatment of ortho- a ino benzonitrile 11 with an organo metallic compound such as organo lithium reagent or Grignard reagent in a suitable solvent such as THF or ether under an inert atmosphere such as argon or mtrogen at temperatures ranging from -78 °C to room temperature as illustrated m Scheme III Benzomtπle 11 can be readily prepared from an appropπately substituted benzomtπle such as bromobenzomtπle 10 usmg a suitable couplmg reaction such as Stille or Suzuki protocol earned out m a similar fashion as descπbed for the preparation of the Weinreb amide 7 Re t or R 6 MgX,0 degrees C Scheme IV illustrates the synthesis of 3,4-dιhydroquιnazolιn-2-ones The substituted 2-amιno benzomtπle 11 is treated with an organo metallic compound such as organo lithium or Gπgnard reagent m a nonprotic solvent such as THF or ether under an mert atmosphere such argon or mtrogen at -78 °C to room temperature to produce an lmino mtermediate which is reacted with a suitable carbonate such as diethyl carbonate or dimethyl carbonate in situ at 0 °C to 60 °C to give quιnazohn-2- ones 12 Protection of qumazolιn-2-ones 12 with a suitable protective group such as >αrα-methoxybenzyl moiety can be effected by treatmg 12 with a suitable base such as potassium hydπde, potassium t-butoxide, or sodium hydπde followed by addition of a protective reagent such as /jαrø-methoxybenzyl chloπde in an appropπate solvent such as DMF, or a mixture of solvents such as THF and DMF under an inert atmosphere such as nitrogen or argon at 0 °C to room temperature. The Michael addition of a suitable organo metallic compound such as organo lithium or Grignard reagent to the protected quinazolin-2-ones 12 to give 13 can be accompUshed in the presence of a suitable Lewis acid such as magnesium triflate in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at 0 °C to room temperature. Removal of protective group can be effected by treating 13 with a suitable deprotecting reagent, e.g. for the /rara-methoxybenzyl protective group it can be removed by treatment of 13 with protic acid such as TFA or with Ceric ammonium nitrate in a suitable solvent such as methylene chloride at 0 ° C to room temperature under an inert atmosphere such as argon or nitrogen. Prior to the removal of protective group, the alkylation of 3-nitrogen can be achieved by treating 13 with an appropπate base such as sodium hydride, potassium hydride, or potassium t-butoxide m a suitable solvent such as DMF followed by quenching the reaction solution with an organo iodide or an organo tπflate such as lodomethane under an mert atmosphere such as argon or mtrogen at 0°C to room temperature The compounds of the present mvention 14 can be accomplished when the protective group is removed with a suitable reagent, e g for the /røra-methoxybenzyl protective group it can be removed by treatment of 13 with protic acid such as TFA or with Ceπc ammomum mtrate m a suitable solvent such as methylene chloride at 0°C to room temperature under an mert atmosphere such as argon or mtrogen The conversion of compounds 14 to 3,4-dιhydroqumazolm-2-thιones 15 can be accompUshed by treatment of 14 with a suitable sulfur reagent such as Lawesson's reagent m a nonprotic solvent such as o-xylene, chlorobenzene, or toluene under an mert atmosphere such as argon or mtrogen at reflux As illustrated m scheme V, the compounds 14 or 15 can be further deπvatized at position- 1 via numerous approaches leadmg to a vaπety of the novel deπvatives mcludmg 1 -alkyl, substituted 1 -alkyl, 1-carbonyl, substituted 1-carbonyl, 1-carboxy, substituted 1-carboxy deπvatives For examples, alkyl or substituted alkyl derivatives 16 or 17 can be effected by treatment of carbamate 14 or 15 with a suitable base such as sodium hydride m a suitable solvent such as DMF under an mert atmosphere such as argon or mtrogen followed by addition of an appropπate electrophile such as alkyl or substituted alkyl bromide, iodide, or tπflate Such transformation of 14 or 15 to 16 or 17 at position- 1 can also be effected using bφhasic condition as mdicated m scheme V m which alkylation is executed usmg a biphasic catalyst such as tπbutylammomum bromide in a suitable solvent such as acetonitπle A further example of such modification m position- 1 mcludes but not limited to the one depicted m scheme V m that heatmg of 14 or 15 with tπethyl orthoformate affords 1 -substituted deπvatives of compound 14 or 15 1 (X=θ) 16 (X=θ) 15 (X=S) 17 (X=S) 18 (X=θ) 19 (X=S) 20 (X=θ) 21 (X=S) The acylation or carboxylation of the compound 14 or 15 at posιtιon-1 to give compound 18 or 19 can be readily effected by treatment of 14 or 15 with a smtable acylatmg or carboxylatmg reagent such as di-t-butyl dicarbonate m the presence of a suitable basic catalyst such as DMAP m a suitable solvent such as acetomtπle under an mert atmosphere such as argon or mtrogen The amination of position- 1 of compound 14 or 15 to give compounds 20 and 21 can be furnished using a suitable aminating reagent such as chloroamme m the presence of a suitable base such as sodium hydride in a suitable solvent such as THF or diethyl ether foUowing the hterature procedure (Metlesics et al. J. Org. Chem. 30, 1311(1965).). According to scheme VI an appropriate aniline such as 4-bromoaniUne 22, is reacted in the presence of a base in a suitable nonprotic solvent with an acryloyl chloride 23 to form the amide 24. The base is preferably a strong base such as sodium hydride or sodium or potassium hexamethyldisilylamide, utilizing THF as the solvent under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent. Scheme VI 26 Lawesson's agent 27 Reaction of the amide 24 under strongly acidic conditions, sulfuric acid, borontrifluoride etherate, or preferably aluminum chloride either as a melt, or in an mert solvent (dichlorobenzenes) under an mert atmosphere (mtrogen or argon) from 0°C up to the reflux temperature, of the solvent then provides the cychc amide 25 Subsequent reaction of compound 25 with an aryl or heteroaryl boromc acid, boromc acid anhydπde or tπalkyl stannane then provides access to the desired biaryl compound 26 The reaction can be carried out m a solvent such as acetone, ethanol, benzene, toluene or THF, under an mert atmosphere (mtrogen or argon) from 0°C up to the reflux temperature of the solvent, m the presence of a palladium catalyst such as tetrakιs(tnphenylphosphιne) palladium (0) or palladium acetate and may require an additive such as sodium carbonate, cesium fluoπde or potassium phosphate The conversion of compounds 26 to thioamide 27 can be accomplished by treatment of 26 with a suitable sulfur reagent such as Lawesson's reagent m a nonprotic solvent such as o-xylene, chlorobenzene, or toluene under an inert atmosphere such as argon or nitrogen at reflux Scheme VII 30 29 31 According to scheme VII, an appropriate cycUc amide such as 25, is allowed to react with NaH in THF to form the anion species and then a benzyl haUde is added to convert the starting material to the N-protected amide product, 28. Reaction of 28 with an aryl boronic acid in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) or palladium acetate permits a coupling of the two aromatic species to yield 29. The reaction is normally carried out under biphasic conditions. That is, water is often employed along with an appropriate organic solvent, such as toluene or DMF. The paUadium catalyst is typically added last and the reaction mixture is refluxed in the presence of an inert gas such as nitrogen. The product is treated with a Grignard Reagent, an alkyl magnesium halide, in THF foUowed by the addition of ammonium chloride solution to afford the enamine derivative 30. The reduction of the double bond in 30 and removal of the protecting group can be accomplished in a single step by catalytic reduction in a Parr Hydrogenation Apparatus using paUadium on charcoal to form the target compound 31 Scheme VIE NaCNBH, 35 3-Fluoro-5-(2,4,4-tπmethyl-l,2,3,4-hydro-qmolmyl)-benzomtπle (compound 35) can be prepared by Scheme VIII, a process similar to Scheme VII Accordmg to scheme VIII, compound 28 is allowed to react with a Gπgnard reagent, an alkyl magnesium hahde, in THF followed by the addition of ammomum chloπde solution to afford the enamine deπvative 32 Reduction of the double bond with sodium cyanoborohydnde affords the reduced derivative 33 Removal of the protectmg group with a strong acid such as trrflic or sulfuπc acid affords the deprotected compound 34 which can then be coupled with a suitably substituted phenylboromc acid m the presence of a paUadium catalyst such as tetrakis(tnphenylphosphme)paUadium(0) or paUadium acetate permits a couplmg of the two aromatic species to yield 35 The reaction is normally earned out under biphasic conditions That is, water is often employed along with an appropπate organic solvent, such as toluene or DMF The compounds of the present mvention can be used in the form of salts deπved from pharmaceuticaUy or physiologically acceptable acids or bases These salts mclude, but are not hmited to, the following salts with morgamc acids such as hydrochloric acid, sulfuπc acid, mtπc acid, phosphoπc acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid Other salts mclude salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium m the form of esters, carbamates and other conventional "pro-drug" forms, which, when admimstered m such form, convert to the active moiety in vivo This mvention mcludes pharmaceutical compositions and treatments which compπse administering to a mammal a pharmaceutically effective amount of one or more compounds as descπbed above wherem G 2 is C=0 as antagomsts of the progesterone receptor The mvention further provides comparable methods and compositions which utilize one or more compounds herem wherem G 2 is C=S as agomsts of the progesterone receptor Moreover the mvention further provides comparable methods and compositions which utilize one or more compounds herem wherem G ι =0 and G 2 are agomsts of the progesterone receptor and when are agomsts of the progesterone receptor The progesterone receptor antagomsts of this mvention, used alone or in combmation, can be utilized m methods of contraception and the treatment and/or prevention of bemgn and malignant neoplastic disease Specific uses of the compounds and pharmaceutical compositions of mvention mclude the treatment and/or prevention of uterme myometnal fibroids, endometriosis, bemgn prostatic hypertrophy, carcinomas and adenocarcinomas of the endometπum, ovary, breast, colon, prostate, pituitary, memngioma and other hormone-dependent tumors Additional uses of the present progesterone receptor antagomsts mclude the synchronization of the estrus in livestock When used m contraception the progesterone receptor antagonists of the current mvention may be used either alone m a continuous administration of between 1 and 500 mg per day, or alternatively used m a different regimen which would entail 2-4 days of treatment with the progesterone receptor antagomst after 21 days of a progestm, m this regimen between 0 1 and 500 mg daily doses of the progestm (e g levonorgestrel, tπmegestone, gestodene, norethistrone acetate, norgestimate or cyproterone acetate) would be foUowed by between 0 1 and 500 mg daily doses of the progesterone receptor antagomsts of the current mvention The progesterone receptor antagomsts of this mvention, used alone or in combmation, can also be utilized m methods of treatment and/or prevention of benign and malignant neoplastic disease Specific uses of the compounds and pharmaceutical compositions of mvention mclude the treatment and/or prevention of uterme myometπal fibroids, endometπosis, benign prostatic hypertrophy, carcmomas and adenocarcmomas of the endometπum, ovary, breast, colon, prostate, pituitary, mernngioma and other hormone-dependent tumors Additional uses of the present progesterone receptor antagomsts mclude the synchronization of the estrus m livestock The progesterone receptor agonists of this mvention, used alone or in combination, can be utilized m methods of contraception and the treatment and/or prevention of dysfunctional bleedmg, uterme leiomyomata, endometriosis, polycystic ovary syndrome, carcmomas and adenocarcmomas of the endometπum, ovary, breast, colon, prostate Additional uses of the mvention mclude stimulation of food intake When used m contraception the progesterone receptor agomsts of the current mvention are preferably used m combmation or sequentiaUy with an estrogen agomst (e g ethmyl estradiol) The preferred dose of the progesterone receptor agomst is between 0 01 and 500 mg per day When the compounds are employed for the above utilities, they may be combmed with one or more pharmaceutically acceptable earners or excipients, for example, solvents, diluents and the Uke, and may be admimstered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containmg, for example, from about 0 05 to 5% of suspendmg agent, syrups containmg, for example, from about 10 to 50% of sugar, and elixirs containmg, for example, from about 20 to 50% ethanol, and the Uke, or parenterally m the form of sterile injectable solutions or suspensions containmg from about 0 05 to 5% suspendmg agent m an isotomc medium Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient m combmation with the earner, more usuaUy between about 5% and 60% by weight These active compounds may be admimstered oraUy as well as by intravenous, intramuscular, or subcutaneous routes Solid earners mclude starch, lactose, dicalcium phosphate, microcrystaUme ceUulose, sucrose and kaolin, while hqmd earners mclude steπle water, polyethylene glycols, non-iomc surfactants and edible oils such as corn, peanut and sesame oils, as are appropπate to the nature of the active ingredient and the particular form of administration desired Adjuvants customarily employed m the preparation of pharmaceutical compositions may be advantageously mcluded, such as flavormg agents, colormg agents, preservmg agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA The prefened pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard- filled or liquid-filled capsules Oral administration of the compounds is prefened These active compounds may also be admimstered parenterally or mtrapentoneaUy Solutions or suspensions of these active compounds as a free base or pharmacologicaUy acceptable salt can be prepared m water suitably mixed with a surfactant such as hydroxypropylceUulose Dispersions can also be prepared m glycerol, liquid, polyethylene glycols and mixtures thereof in oils Under ordinary conditions of storage and use, these preparations contam a preservative to prevent the growth of microorganisms The pharmaceutical forms smtable for injectable use mclude sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exits It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi The earner can be a solvent or dispersion medium containmg, for example, water, ethanol (e g , glycerol, propylene glycol and hqmd polyethylene glycol), suitable mixtures thereof, and vegetable oil The foUowmg non-limiting examples are Ulustrative of the mvention EXAMPLE 1 l-(4-Amino-3'-chloro-biphenyl-3-yl)-ethanone A mixture of 2-ammo-5-bromo-N-methoxy-N-methylbenzamιde (7 78g, 30 mmol), 3-chlorophenyl boromc acid (5 63g, 36 mmol), tetrakιs(tnphenylphosphme)paUadιum (0) (1 73g, 1 5 mmol), and sodium carbonate (7 63g, 72 mmol) m a mixture of DME and water (150 mL/30 mL) was degassed to remove the oxygen and was then heated at 85 °C under mtrogen for 3 hours The reaction mixture was cooled to room temperature and treated with brine (30 mL) and ethyl acetate (100 mL) The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x40 mL) The combmed organic layers were washed with brme and dπed with MgS0 After removal of solvent, the residue was purified by a flash chromatography (sihca gel, hexane ethyl acetate/1 1) to give 5-(3- chlorophenyl)-N-methoxy-N-methylbenzamιde as a brown oil (5g, 57%) To a solution of this benzamide (5g, 17 2 mmol) in anhydrous THF was added m a dropwise fashion a solution of methyUithium in ether (1 4M, 28 6 mL, 40 mL) at -78 °C under mtrogen After stirring for 30 minutes, the reaction mixture was treated with a saturated aqueous ammonium chloπde solution (50 mL) at -78 °C Ethyl acetate (100 mL) was added, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3x20 mL) The combmed organic layers were washed (brme) and dned (MgS0 4 ) After removal of solvent, the residue was puπfied by a flash chromatography (silica gel, hexane ethyl acetate/2 1) to afford l-(4-ammo-3'- chloro-bιphenyl-3-yl)-ethanone as yellow solid (2g, 47%) mp 89-90 °C, Η-NMR (CDC1 3 ) δ 7 89 (d, 1H, J= 2 0 Hz), 7 51 (m, 2H), 7 25-7 40 (m, 3H), 6 73 (d, 1H, J = 8 6 Hz), 6 38 (br, 2H), 2 65 (s, 3H), MS (El) m/z 268([M+Na] + , 60%), Anal Calc For C ]4 H 12 C1N0 C, 68 44, H, 4 92, N, 5 70 Found C, 68 40, H, 4 89, N, 5 61 EXAMPLE 2 l-(4-Amino-3 , -chloro-biphenyl-3-yl)-dimethyl-methanol To a solution of l-(4-ammo-3'-chloro-bιphenyl-3-yl)-ethanone ( 55g, 2 2 mmol) in anhydrous THF under nitrogen was added a solution of methyl magnesium bromide (3 0 M in diethyl ether, 1 mL, 3 mmol) at 0 °C The mixture was slowly warmed to room temperature and kept stirring under mtrogen for 18 hours The mixture was treated with 10 mL of saturated ammomum chloride aqueous solution and ethyl acetate (50 mL) was added The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x15 mL) The combmed organic layers were washed with brme (20 mL) and dried (MgS0 ) After removal of the solvent, the residue was puπfied by a flash chromatography (silica gel, hexane ethyl acetate/2 1) to afford the title compound as an off-white solid 186-188 °C (HC1 salt) Anal Calc For Cι 5 H 17 Cl 2 NO C, 60 42, H, 5 75, N, 4 7 Found C, 60 51, H, 5 62, N, 4 56 EXAMPLE 3 6-(3-Chloro-phenyl)-2A4-trimethv--2-trifluoromethyl-l,4-dihvdro-2H- benzofdl [l-,31oxazine A mixture of (4-ammo-3 -chloro-bφhenyl-3-yl)-dιmethyl-methanol (0 25 g, 0 95 mmol), tπfluoromethylacetone (0 16 g, 1 43 mmol), and / toluenesulfonιc acid (0 01 g, 0 05 mmol) in dry toluene (5 mL) was stirred under a blanket of nitrogen for 48 hours Upon completion of the reaction, the toluene was removed and the residue purified via flash chromatography (silica gel, 10% ethyl acetate/hexane) to give 6-(3- chloro-phenyl)-2,4,4-tπmethyl-2-tnfluoromethyl- 1 ,4-dιhydro-2H-benzo[d] [1,3]- oxazine (0 22 g, 65%) as a clear oil The oil was dissolved m ether at -78 °C and then treated with a solution of IN HC1 m ether to give the hydrochlonde salt of the title compound as a white sohd Η-NMR (OMSO-d 6 ) δ 7 67 (bs, 1H), 7 58 (d, 1H, J = 7 88 Hz), 7 42 (m, 3H), 7 32 (d, 1H, J= 7 96 Hz), 6 84 (d, 1H, J= 8 03 Hz), 1 52 (s, 3H), 1 5 (s, 6H), MS (APCI) m/z 354 ([M-H]\ 100%), Anal Calc For C 18 H 17 C1F 3 N0 C, 55 12, H, 4 62, N, 3 57 Found C, 54 97, H, 4 59, N, 3 41 EXAMPLE 4 6-(3-Chloro-phenyl)-2--,2-,4-,4-tetramethyl-l-,4-dihvdro-2H-benzo[dl [l-,31oxazine A mixture of (4-ammo-3 -chloro-bιphenyl-3-yl)-dιmethyl-methanol (0 46 g, 1 8 mmol), acetone (0 16 g, 2 7 mmol), and/7-toluenesulfonιc acid (0 017 g, 0 09 mmol) in dry toluene (6 mL) was heated at 33 °C under a blanket of mtrogen overnight Upon completion of the reaction, the toluene was removed and the compound purified via a flash chromatography (silica gel, 15% ethyl acetate/hexane) to give 6-(3-chloro- phenyl)-2,2,4,4-tetramethyl-l,4-dιhydro-2H-benzo[d][l,3]oxazme (0 36 g, 68%) as a yellow oil The oil was dissolved m ether at -78 °C and then treated with a solution of IN HC1 in ether to give the hydrochlonde salt of the title compound as a yellow solid Η-NMR (DMSO-c^) δ 7 70 (bs, 1H), 7 61 (d, 1H, J= 1 82 Hz), 7 52 (bs, 1H), 7 44 (m, 2H), 7 33 (d, 1H, J= 8 21 Hz), 6 87 (d, 1H, J= 7 85 Hz), ) 5 (s, 6H), 1 4 (s, 6H), MS (ESI) m/z 302 ([M+H] + , 100%), Anal Calc For C 18 H 20 C1NO C, 63 91, H, 6 26, N, 4 14 Found C, 64 08, H, 6 43, N, 4 14 EXAMPLE 5 6-(3-Nitro-phenyl)-2-,2,4-,-t-rimethyl-l-,4-dihvdro-2H-benzo[dUl < 31oxa--ine Prepared from l-(4-ammo-3'-mtro-bιphenyl-3-yl)-ethanol and acetone m the same fashion as that of Example 4 Yellow solid mp 188-189 °C, Anal Calc For C, 7 H 18 N 2 O 3 -0 35 H 2 0 C, 67 02, H, 6 19, N, 9 20 Found C, 66 7, H, 5 89, N, 9 03 EXAMPLE 6 4-Amino-3'-chloro-biphenyl-3-carbonitrile A mixture of 2-ammo-5-bromobenzomtnle (lOg, 50 mmol), 3-chlorophenyl boromc acid (9 5g, 60 mmol), tetrakιs(tπphenylphosphme)-paUadιum (0) (3 5g, 3 mmol), and sodium carbonate (13g, 120 mmol) m a mixture of DME and water (100 mL/25 mL) was degassed to remove the oxygen and then heated to 85 °C under a blanket of mtrogen for 5 hours The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammomum chloride solution (80 mL) Ethyl acetate (200 mL) was added, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3x40 mL) The combmed organic layers were washed with brme and dπed with MgS0 4 The solvent was removed in vacuo and the residue was purified by a silica gel flash chromatography (hexane ethyl acetate/4 1) to afford 4-ammo-3'-chloro-bιphenyl-3-carbomtπle as an off-white sohd (8g, 87%) mp 118-119 °C, Η-NMR (DMSO--4) δ 7 80 (d, IH, J= 2 3 Hz), 7 65- 7 72 (m, 2H), 7 57 (d, IH, J= 8 0 Hz), 7 42 (t, IH, J= 7 9 Hz), 7 31 (m, IH), 6 87 (d, IH, J= 8 7 Hz), 6 29 (br, 2H), Anal Calc For C 13 H 9 C1N 2 C, 68 28, H, 3 97, N, 12 25 Found C, 67 68, H, 4 06, N, 11 89 EXAMPLE 7 6-(3-ChIorophenvD-4-cvclopropyl-lH-quinazolin-2-one Prepared using a similar procedure as described m the literature (Tucker et al J Med Chem , 1994, 37, 2437-2444) To a solution of cyclopropyhnagnesium bromide prepared from magnesium (0 9g, 37 mmol) and cyclopropyl bromide (3 2 mL, 40 mmol) m anhydrous THF was added at 50 °C under mtrogen a solution of 4-amιno- 3'-chloro-bιphenyl-3-carbonιtπle (2 3g, 10 mmol) m anhydrous THF After addition, the reaction mixture was kept at 50 °C for 30 minutes under mtrogen and treated with dimethyl carbonate m a dropwise manner The reaction solution was stined at 50 °C under mtrogen for 30 minutes and cooled to ambient temperature A saturated aqueous ammonium chloride solution (30 mL) was added followed by addition of ethyl acetate (80 mL) The orgamc layer was separated and the aqueous layer was extracted with ethyl acetate (3x40 mL) The combmed orgamc layers were washed with brme and dried with MgS0 4 After removal of the solvent, the residue was punned by a flash chromatography (sihca gel, methylene chlonde methanol/25 1) to give 6-(3- chlorophenyl)-4-cyclopropyl-lH-qumazolm-2-one as ayeUowish sohd (0 55g, 18%) mp 189-190 °C, Η-NMR (OMSO-d 6 ) δ 11 71 (s, IH, D 2 0 exchangeable), 8 56 (d, IH. J= 1 3 Hz), 8 09 (dd, IH, J= 8 6, 1 6 Hz), 7 92 (s, IH), 7 77 (d, IH, J= 7 7 Hz), 7 52 (t, IH, J= 7 9 Hz), 7 45 (d, IH, J= 8 1 Hz), 7 36 (d, IH, J = 8 6 Hz), 3 15 (m, IH), 1 20 (m, 4H), MS (Cϊ) m/z 291 ([M+H] + , 100%), Anal Calc For C 17 H, 3 C1N 2 0 C, 69 98, H, 4 49, N, 9 23 Found C, 67 98, H, 4 46, N, 9 10 EXAMPLE 8 6-(3-Chlorophenyl)-4-cvclopropyl-l-(4-methoxybenzyl)-lH-quinazolin-2-one To a suspension of 6-(3-chlorophenyl)-4-cyclopropyl-lH-qumazolm-2-one (0 5g, 1 68 mmol) m anhydrous DMF was added potassium hexmethylsilyl amide (0 45g, 2 1 mmol) at ambient temperature under mtrogen The reaction mixture was stirred at ambient temperature for 30 minutes, treated wιth/?-methoxy benzyl chlonde (0 35 mL, 2 5 mmol), and heated at 55°C for 5 hours The mixture was then cooled to room temperature and quenched with a saturated aqueous ammomum chloride solution (10 mL) Methylene chlonde (50 mL) was added and orgamc layer was separated The aqueous layer was extracted with methylene chloride (2x20 mL) and the combmed orgamc layers were washed with brme and dned (MgS0 4 ) After removal of solvent, the residue was separated on a flash chromatography (sihca gel, hexane ethyl acetate/1 1) to afford 6-(3-chlorophenyl)-4-cyclopropyl-l-(4-methoxybenzyl)-lH- quιnazohn-2-one as an off-white solid mp 173-174 °C, Η-NMR (DMSO-< ) δ 8 65 (d, IH, J= 1 8 Hz), 8 10 (dd, IH, J= 8 9, 1 8 Hz), 7 93 (d, IH, J= 1 6 Hz), 7 79 (d, IH, J= 7 6 Hz), 7 53 (d, 2H, J= 8 4 Hz), 7 46 (t, IH, J= 8 1 Hz), 7 21 (d, 2H, J = 8 6 Hz), 6 88 (d, 2H, J= 8 6 Hz), 5 41 (s, 2H), 3 73 (s, 3H), 3 18 (m, IH), 1 18-1 27 (m, 4H), MS (CI) m/z 417([M+H] + , 100%), Anal Calc For C 25 H 2 ιClN 2 0 2 C, 72 02, H, 5 08, N, 6 72 Found C, 71 88, H, 4 91, N, 6 70 6-(3-Chlorophenyl)-4-cyclopropyl-2-(4-methoxybenzyloxy)qumazolme was obtamed as a side product, off-white sohd mp 158-159 °C, Η-NMR (DMSO--4) δ 8 75 (d, IH, J= 1 7 Hz), 8 26 (dd, IH, J= 8 8, 1 8 Hz), 8 01 (s, IH), 7 84 (m, 2H), 7 56 (t, IH, J= 7 9 Hz), 7 45 (m, 3H), 6 96 (d, 2H, J= 8 6 Hz), 5 38 (s, 2H), 3 75 (s, 3H), 3 24 (m, IH), 1 25 (m, 4H), MS (CI) m/z 417([M+H] + , 100%), Anal Calc For C 25 H 21 C1N 2 0 2 C, 72 02, H, 5 08, N, 6 72 Found C, 72 19, H, 4 91, N, 6 65 EXAMPLE 9 6-(3-ChlorophenyI)-4-cvclopropyl-4-methyl-3-,4-dihvdro-lH- q uinazolin-2-one To a solution of 6-(3-chlorophenyl)-4-cyclopropyl-l-(4-methoxybenzyl)-lH- quιnazolιn-2-one (0 25g, 0 6 mmol) m anhydrous ether was added, at ambient temperature under nitrogen, magnesium triflate (0 78g, 2 4 mmol) The mixture was stirred for 30 mmutes and treated with a solution of methylmagnesium bromide m ether (3 0 M, 1 0 mL, 3 0 mmol) The reaction mixture was kept at room temperature under mtrogen for 3 hours and quenched with a mixture of a saturated aqueous ammomum chloride solution (10 mL) and IN aqueous HC1 solution (5 mL) The mixture was stined at room temperature for 20 mmutes and ethyl acetate (40 mL) was added The orgamc layer was separated and the aqueous layer was extracted with ethyl acetate (3x10 mL) The combmed orgamc layers were washed with bnne and dπed (MgS0 4 ) The solvent was removed and a half portion of the residue was dissolved m TFA (3 mL) and was stirred under mtrogen at room temperature for 72 hours The solution was poured onto ice-water and the white precipitate obtamed was coUected on a filter The solid was washed with water and then purified by a flash chromatography (methylene chloride methanol/25 1, sihca gel) to give 6-(3- chlorophenyl)-4-cyclopropyl-4-methyl-3 ,4-dιhydro- 1 H-quιnazolιn-2-one as off-white sohd(40 mg, 43%) mp 125-127 °C, Η-NMR (DMSO-^) δ 9 21 (s, IH), 7 71 (s, IH), 7 61 (d, IH, J= 7 8 Hz), 7 55 (d, IH, J= 1 6 Hz), 7 47 (dd, IH, J= 8 3, 1 8 Hz), 7 45 (t, IH, J = 7 8 Hz), 7 36 (d, IH, J= 8 1 Hz), 6 84 (d, IH, J= 8 2 Hz), 6 79 (s, IH), 1 54 (s, 3H), 1 11 (m, IH), 0 42 (m, IH), 0 15-0 20 (m, 3H), MS (ESI) m/z 313([M+H] + , 100%) EXAMPLE 10 6-(3-Chlorophenyl)-4-cvclopropyl-3-,4-dimethyl-3 t 4-dihvdro-lH-quinazolin-2-one To a solution of half of the crude addition product from Example 9 m anhydrous DMF (5 mL) was added under mtrogen at room temperature sodium hydπde (25 mg, 0 63 mmol) The mixture was stirred at ambient temperature for 30 mmutes and treated with methyl iodide (0 5 mL, excess) After stirring for 3 5 hours, a mixture of saturated aqueous ammomum chloπde and IN HC1 aqueous solution (10 mL/5 mL) was added to the reaction mixture Ethyl acetate (30 mL) was added and orgamc layer was separated The aqueous layer was extracted with ethyl acetate (3x10 mL) and the combmed organic layers were washed with brine and dπed (MgS0 4 ) The solvent was removed and residue was dissolved m a mixture of methylene chlonde and TFA (2 mL/2 mL) After stirring for 3 hours, the solution was poured onto ice-water and neutralized by addition of a saturated aqueous sodium bicarbonate solution The ethyl acetate (30 mL) was added and orgamc layer was separated The aqueous layer was extracted with ethyl acetate (3x10 mL) The combmed orgamc layers were washed with brme and dried (MgS0 4 ) The solvent was removed in vacuo and the residue was puπfied by a flash chromatography (silica gel, hexane ethyl acetate/ 1 1) to afford 6-(3-chlorophenyl)-4-cyclopropyl-3,4-dιmethyl-3,4-dιhydro-lH-qumazohn-2- one as a white sohd (11 mg, 11% for three steps) mp 193-194 °C, Η-NMR (DMSO- d 6 ) δ 9 51 (s, IH), 7 68 (s, IH), 7 59 (d, IH, J = 8 0 Hz), 7 57 (d, IH, J= 1 6 Hz), 751 (dd, IH, J = 83, 17 Hz), 746 (t, IH, J = 78 Hz), 735 (d, IH, J = 81 Hz), 687 (d, IH, J = 83 Hz), 302 (s, 3H), 151 (s, 3H), 125 (m, IH), 032-051 (m, 3H), 025 (m, IH), MS (CI) m/z 327 ([M+H] + , 100%) Anal Calc For C 19 H 19 ClN 2 O-03 H 2 0 C, 6869, H, 595, N, 843 Found C, 6869, H, 570, N, 818 EXAMPLE 11 6-(3-ChIoro-phenyl)-4,4-dimethyl-3,4-dihvdro-lH-quinolin-2-one Sodium hydπde (1 16 g, ca 29 mmol, 60% m oil) was washed with hexane (x3) then placed m anhydrous THF (50 mL) under mtrogen To this slurry was then added dropwise a solution of 4-bromoanιlιne (5 0 g, 29 mmol) m dry THF (100 ml) After 0 5 h, the mixture was cooled to 0 °C and treated with a solution of 3,3- dimethylacryloyl chlonde m anhydrous THF (30 ml) After 4 h, the mixture was quenched with saturated aqueous ammomum chlonde solution, and extracted with diethyl ether The organic layer was washed with water, brme, dried (Na 2 S0 4 ) and evaporated The residue was then crystallized from EtOAc/hexane to afford N-(3,3'- dιmethylacryoloyl)-4-bromoamlme (3 36 g, 13 22 mmol, 46%) as a white solid ] H ΝMR (CDC1 3 ) δ 7 42 (s, 4H), 7 06 (s, IH), 5 68 (s, IH), 2 21 (s, 3H), 1 09 (s, 3H), MS (El) m/z 253 [M + ] N-(3,3'-Dιmethylacryoloyl)-4-bromoamUne (4 0 g, 15 38 mmol) was heated under nitrogen to ca 130 - 140 °C causing the sohd to melt Aluminum chloride (3 07 g, 23 mmol) was added and heatmg contmued After 1 h, the mixture was cooled and quenched carefully with water and then extracted with dichloromethane (3x60 mL) The combmed orgamc layers were washed with water, dried (MgS0 4 ) and evaporated The residue was then subjected to column chromatography (Sι0 2 , EtOAc/hexane gradient elution) to afford 6-bromo-4,4-dιmethyl-3,4-dιhydro-lH-qumolm-2-one (1 69g, 6 6 mmol, 47%) as a white sohd ] H-ΝMR (CDC1 3 ) δ 8 82 (s, IH), 7 39 (d, IH, J = 2 Hz), 7 29 (dd, IH, J = 8 3, 2 0 Hz), 6 71 (d, IH, J = 8 0 Hz), 2 47 (s, 2H), 1 32 (s, 6H) To a solution of the last cited compound (0 5 g, 1 96 mmol) in dimethoxyethane (15 mL) was added tetrakιs(tπphenylphosphιne)paUadιum (0) (0 11 g, 0 09 mmol) under mtrogen After 15 mm , 3-chlorophenylboronιc acid (0 6 g, 3 9 mmol) was added followed by potassium carbonate (1 62 g, 11 7 mmol) m water (7 5 mL) After 1 5 h at reflux, the mixture was cooled, filtered, and extracted with EtOAc The orgamc layer was washed with water, dned (MgS0 ) and evaporated The residue was then subjected to column chromatography (Sι0 2 , EtOAc hexane/3 1) and crystallized from dichloromethane/hexane to afford 6-(3-chloro-phenyl)-4,4- dιmethyl-3,4-dιhydro-lH-qumolm-2-one (0 21 g, 0 73 mmol, 37%) as a white solid, mp 211 - 215 °C, ! H-NMR (CDC1 3 ) δ 8 48 (s, IH), 7 53 (s, IH), 7 47 (d, IH, J = 2 0 Hz), 7 44 - 7 29 (m, 4H), 6 87 (IH, d, J = 2 0 Hz), 2 54 (s, 2H), 1 39 (s, 6H), MS ((- )ES) m/z 284 [M-H] " EXAMPLE 12 - Pharmacology The compounds of this invention were tested m the relevant assay as described below and their potency are m the range of 0 01 nM to 5 μM m the in vitro assays and 0 001 to 300 mg/kg m the in vivo assays The selected examples are listed below Table 1 hPR CV-1 Compound Ri R 2 Ra TCso (nM) Me Me CI 10 0 CF, Me CI 50 0 Me H N0 2 1675 R = H, hPR CV-1, ICso = 1075 nM hPR CV-1, ICso = 1075 nM R = Me, hPR CV-1, IC 50 = 580 nM A In-vitro biology The m-vitro biology is determmed by (1) competitive Radio ligand Binding using the A-form of the human progesterone receptor with progesterone as the radiohgand, (2) co-transfection assay, which provides functional activity expressed as agonist EC50 and Antagomst IC50 values, (3) a T47D cell proliferation, which is a further functional assay which also provides agomst and antagonist data, and (4) T47D cell alkaline phosphatase assay, which is a further functional assay which also provides agomst and antagomst data 1. hPR Binding assay - This assay is carried out m accordance with Pathirana, C , Stem, R B , Berger, T S , Femcal, W , laniro, T , Mais, D E , Torres, A , Glodman, M E , Nonsteroidal human progesterone receptor modulators from the marine alga cymopha barbata, J Steroid Biochem. Mol Biol , 1992, 41, 733-738 2. PRE-luciferase assay m CV-1 ceUs The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity m CV-1 ceUs co-transfected with human PR and PRE-luciferase plasmids The materials methods used in the assay are as follows a Medium The growth medium was as follows DMEM (BioWhittaker) contaimng 10% (v/v) fetal bovme serum (heat mactivated), 0 1 mM MEM non-essential ammo acids, lOOU/ml pemcilhn, lOOmg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) The expenmental medium was as foUows DMEM (BioWhittaker), phenol red-free, contaimng 10% (v/v) charcoal-stπpped fetal bovme serum (heat-mactivated), 0 1 mM MEM non-essential ammo acids, lOOU/ml pemciUm, lOOmg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) b CeU culture, transfection. treatment- and luciferase assay Stock CV-1 ceUs are maintained m growth medium Co-transfection is done using 1 2xl0 7 ceUs, 5 mg pLEM plasmid with hPR-B inserted at Sphl and BamHl sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg somcated calf thymus DNA as earner DNA m 250 ml Electroporation is carried out at 260 V and 1,000 mF m a Biorad Gene Pulser II After electroporation, ceUs are resuspended m growth medium and plated m 96-well plate at 40,000 cells/well m 200 μl Following overnight mcubation, the medium is changed to expenmental medium Cells are then treated with reference or test compounds m experimental medium. Compounds are tested for antiprogestational activity m the presence of 3 nM progesterone Twenty-four hr after treatment, the medium is discarded, ceUs are washed three times with D-PBS (GIBCO, BRL) Fifty μl of cell lysis buffer (Promega, Madison, WI) is added to each weU and the plates are shaken for 15 mm m a Titer Plate Shaker (Lab Lme Instrument, Inc ) Luciferase activity is measured using luciferase reagents from Promega c Analysis of Results Each treatment consists of at least 4 replicates Log transformed data are used for analysis of variance and nonlinear dose response curve fittmg for both agomst and antagonist modes Huber weightmg is used to downweight the effects of outliers EC 50 or IC 50 values are calculated from the retransformed values JMP software (SAS Institute, Inc ) is used for both one-way analysis of variance and non-linear response analyses d Reference Compounds Progesterone and tπmegestone are reference progestrns and RU486 is the reference antiprogestm All reference compounds are run m full dose- response curves and the EC50 or IC50 values are calculated Table 2. Estimated EC50, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies EC50 95% CI Compound Exp (nM) SE lower upper Progesterone 1 0616 0026 0509 0746 2 0402 0019 0323 0501 3 0486 0028 0371 0637 Tπmegestone 1 00075 00002 00066 00085 2 00081 00003 00070 00094 3 00067 00003 00055 00082 Table 3. Estimated IC50, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies IC 50 95% CI Compound Exp (nM) SE lower upper RU486 1 0028 0002 0 019 0 042 2 0037 0002 0 029 0 048 3 0019 0001 0 013 0 027 Progestational activity Compounds that mcrease PRE-luciferase activity significantly (p<0 05) compared to vehicle control are considered active Antiprogestational activity Compounds that decrease 3 nM progesterone mduced PRE-luciferase activity significantly (p<0 05) EC 5 o Concentration of a compound that gives half-maximal mcrease PRE- luciferase activity (default-nM) with SE IC 50 Concentration of a compound that gives half-maximal decrease m 3 nM progesterone mduced PRE-luciferase activity (default-nM) with SE 3 T47D cell proliferation assay The objective of this assay is the determination of progestational and antiprogestational potency by usmg a cell proliferation assay m T47D cells A compound's effect on DNA synthesis m T47D cells is measured The materials and methods used m this assay are as follows a Growth medium DMEM F12 (1 1) (GIBCO, BRL) supplemented with 10% (v/v) fetal bovme serum (not heat- lnactivated), lOOU/ml pemcilhn, lOOmg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) b Treatment medium Minimum Essential Medium (MEM) (#51200-038GIBCO, BRL) phenol red-free supplemented with 0 5% charcoal stripped fetal bovine serum, lOOU/ml pemciUm, 200 mg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) c Cell culture Stock T47 D cells are maintained m growth medium For BrdU mcorporation assay, cells are plated m 96-weU plates (Falcon, Becton Dickmson Labware) at 10,000 cells/well m growth medium After overnight incubation, the medium is changed to treatment medium and ceUs are cultured for an additional 24 hr before treatment Stock compounds are dissolved in appropπate vehicle (100% ethanol or 50% ethanol 50% DMSO), subsequently diluted m treatment medium and added to the cells Progestin and antiprogestm reference compounds are run in full dose-response curves The final concentration of vehicle is 0 1% In control wells, cells receive vehicle only Antiprogestins are tested m the presence of 0 03 nM tπmegestone, the reference progestm agonist Twenty-four hours after treatment, the medium is discarded and ceUs are labeled with 10 mM BrdU (Amersham Life Science, Arlington Heights, IL) m treatment medium for 4 hr d Cell Proliferation Assay At the end of BrdU labeling, the medium is removed and BrdU mcorporation is measured usmg a ceU proliferation ELISA kit (#RPN 250, Amersham Life Science) accordmg to manufacturer's instructions Bnefly, ceUs are fixed m an ethanol contammg fixative for 30 mm, followed by mcubation m a blockmg buffer for 30 mm to reduce background Peroxidase-labeled anti-BrdU antibody is added to the wells and mcubated for 60 mm The cells are rinsed three times with PBS and mcubated with 3,3'5,5'-tetramethylbenzιdιne (TMB) substrate for 10-20 mm dependmg upon the potency of tested compounds Then 25 μl of 1 M sulfuπc acid is added to each weU to stop color reaction and optical density is read m a plate reader at 450 nm within 5 mm e Analysis of Results Square root-transformed data are used for analysis of vanance and nonlinear dose response curve fittmg for both agomst and antagomst modes Huber weightmg is used to downweight the effects of outliers EC 50 or IC 50 values are calculated from the retransformed values JMP software (SAS Institute, Inc ) is used for both one-way analysis of variance and non-hnear dose response analyses m both single dose and dose response studies f Reference Compounds Tπmegestone and medroxyprogesterone acetate (MPA) are reference progestrns and RU486 is the reference antiprogestin AU reference compounds are run m full dose-response curves and the EC50 or IC 50 values are calculated Table 4. Estimated EC50, standard error (SE), and 95% confidence intervals (CI) for individual studies Compound Exp (nM) SE lower upper Tπmegestone 1 0 017 0 003 0 007 0 040 2 0 014 0 001 0 011 0 017 3 0 019 0 001 0 016 0 024 MPA 1 0 019 0 001 0 013 0 027 2 0 017 0 001 0 011 0 024 Table 5. Estimated ICso, standard error, and 95% confident interval for the antiprogestin, RU486 Compound Exp (nM) SE lower upper RU486 1 0 011 0 001 0 008 0 014 2 0 016 0 001 0 014 0 020 3 0 018 0 001 0 014 0 022 EC 50 Concentration of a compound that gives half-maximal mcrease m BrdU mcorporation with SE, IC50 Concentration of a compound that gives half-maximal decrease m 0 1 tπmegestone induced BrdU mcorporation with SE 4 T47D ceU alkalme phosphatase assay The purpose of this assay is to identify progestrns or antiprogestins by determmmg a compound's effect on alkalme phosphatase activity m T47D cells The materials and methods used in this assay are as follows a. Culture medium DMEM F12 (1 1) (GIBCO, BRL) supplemented with 5% (v/v) charcoal stnpped fetal bovme serum (not heat-mactivated), lOOU/ml penicillin, 100 μg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) b Alkaline phosphatase assay buffer I 0 1 M Tπs-HCl, pH 9 8, contaimng 0 2% Tnton X-100 II 0 1 M Tns-HCl, pH 9 8 contaimng 4 mM p-mtrophenyl phosphate (Sigma) c Cell Culture and Treatment Frozen T47D ceUs were thawed m a 37°C water bath and dduted to 280,000 ceUs/ml m culture medium To each well m a 96-weU plate (Falcon, Becton Dickinson Labware), 180 μl of dduted ceU suspension was added Twenty μl of reference or test compounds dUuted m the culture medium was then added to each well When testmg for progestm antagomst activity, reference antiprogestms or test compounds were added m the presence of 1 nM progesterone The cells were mcubated at 37°C in a 5% C0 2 /humιdιfied atmosphere for 24 hr d Alkalme Phosphatase Enzyme Assay At the end of treatment, the medium was removed from the plate and fifty μl of assay buffer I was added to each well The plates were shaken m a titer plate shaker for 15 mm Then 150 μl of assay buffer II was added to each well Optical density measurements were taken at 5 mm intervals for 30 mm at a test wavelength of 405 nM e Analysis of Results Analysis of dose-response data For reference and test compounds, a dose response curve is generated for dose (X-axis) \s the rate of enzyme reaction (slope) (Y-axis) Square root-transformed data are used for analysis of vanance and nonlinear dose response curve fittmg for both agonist and antagomst modes Huber weightmg is used to downweight the effects of outliers EC 5 o or IC 5 o values are calculated from the retransformed values JMP software (SAS Institute, Inc ) is used for both one-way analysis of variance and non-linear dose response analyses m both single dose and dose response studies f Reference Compounds Progesterone and tπmegestone are reference progestrns and RU486 is the reference antiprogestm All reference compounds are run m full dose response curves and the EC50 or IC50 values are calculated Table 6. Estimated EC50, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three independent experiments EC50 95% CI Compound Exp (nM) SE lower upper Progesterone 1 0 839 0 030 0 706 0 996 2 0 639 0 006 0 611 0 669 3 1 286 0 029 1 158 1 429 Tπmegestone 1 0 084 0 002 0 076 0 091 2 0 076 0 001 0 072 0 080 3 0 160 0 004 0 141 0 181 Table 7. Estimated IC50, standard error, and 95% confident interval for the reference antiprogestin RU486 from three independent experiments IC 50 95% CI Compound Exp (nM) SE lower upper RU486 1 0 103 0 002 0 092 0 115 2 0 120 0 001 0 115 0 126 3 0 094 0 007 0 066 0 134 B. In-vivo Biology The primary m-vivo assay is the rat decidualization model which may be used to determine progestational effects of both agonists and antagomsts The secondary m- vivo assay is the rat ovulation inhibition model which is under development and hence the protocol is un-available 1 Rat deciduahzation assay The objective of this procedure is used to evaluate the effect of progestrns and antiprogestms on rat uterme deciduahzation and compare the relative potencies of vanous test compounds The matenals and methods used in this assay are as foUows a Methods: Test compounds are dissolved m 100% ethanol and mixed with corn oil (vehicle) Stock solutions of the test compounds m oil (Mazola ) aj- e then prepared by heatmg (-80 °C) the mixture to evaporate ethanol Test compounds are subsequently diluted with 100% corn oil or 10% ethanol m corn oil prior to the treatment of animals No difference m decidual response was found when these two vehicles were compared b Animals (RACUC protocol #5002) Ovaπectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtamed from Tacomc (Tacomc Farms, NY) foUowmg surgery Ovaπectomy is performed at least 10 days pπor to treatment to reduce circulating sex steroids Animals are housed under 12 hr light/dark cycle and given standard rat chow and water ad libitum c Treatment Rats are weighed and randomly assigned to groups of 4 or 5 before treatment Test compounds in 0 2 ml vehicle are administered by subcutaneous injection m the nape of the neck or by lavage usmg 0 5 ml The animals are treated once daily for seven days For testmg antiprogestms, animals are given the test compounds and a EC50 dose of progesterone (5 6 mg/kg) duπng the first three days of treatment Folio wing decidual stimulation, animals contmue to receive progesterone until necropsy four days later d Dosing Doses are prepared based upon mg/kg mean group body weight In all studies, a control group receiving vehicle is mcluded Determination of dose-response curves is carried out usmg doses with half log mcreases (e g 0 1, 0 3, 1 0, 3 0 mg/kg ) e Decidual mduction Approximately 24 hr after the third injection, deciduahzation is induced in one of the uterme horns by scratching the antimesometπal luminal epithelium with a blunt 21 G needle The contralateral horn is not scratched and serves as an unstimulated control Approximately 24 hr following the final treatment, rats are sacrificed by C02 asphyxiation and body weight measured Uteri are removed and trimmed of fat Decidualized (D-horn) and control (C-horn) uterine horns are weighed separately f Analysis of Results The mcrease m weight of the decidualized uterme horn is calculated by D-horn/C-horn and loganthmic transformation is used to maximize normality and homogeneity of variance The Huber M-estimator is used to down weight the outlymg transformed observations for both dose-response curve fittmg and one-way analysis of vaπance JMP software (SAS Institute, Inc ) is used for both oneway ANOVA and non-linear dose-response analyses g Reference Compounds AU progestm reference compounds were run m fuU dose- response curves and the EC50 for uterme wet weight were calculated Table 8. Estimated ECso, standard error (SE), and 95% confidence intervals for individual studies Compound Exp (mg/kε. s c ) SE lower upper Progesterone 1 5 50 0 77 4 21 7 20 2 6 21 1 12 4 41 8 76 3-Ketodesogestrel 1 0 11 0 02 0 07 0 16 2 0 10 0 05 0 11 0 25 3 0 06 0 03 0 03 0 14 Levonorgestrel 1 0 08 0 03 0 04 0 16 2 0 12 0 02 0 09 0 17 3 0 09 0 02 0 06 0 13 4 0 09 0 02 0 06 0 14 MPA 1 0 42 0 03 0 29 0 60 2 0 39 0 05 0 22 0 67 3 0 39 0 04 0 25 0 61 Table 9. Estimated average EC50, standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds EC50 95% CI Compound (mg/kε. s c ) SE lower upper Progesterone 5 62 0 62 4 55 7 00 3-Ketodesogestrel 0 10 0 02 0 07 0 14 Levonorgestrel 0 10 0 01 0 08 0 12 Table 10. Estimated ICso, standard error, and 95% confident interval for the antiprogestin, RU 486 ICso 95% CI Compound Exp (mε/kg. p o ) SE lower upper RU 486 1 0 21 0 07 0 05 0 96 2 0 14 0 02 0 08 0 27 Concentration Compound concentration m assay(default-mg/kg body weight) Route of administration Route the compound is admimstered to the animals Body weight Mean total animal body weight (default-kg) D-horn Wet weight of decidualized uterme horn (default-mg) C-horn Wet weight of control uterme horn (default-mg) Decidual response [(D-C)/C]xl00% Progestational activity Compounds that mduce deciduahzation significantly (p<0 05) compared to vehicle control are considered active Antiprogestational activity Compounds that decrease ECso progesterone mduced deciduahzation significantly (p<0 05) ECso for uterme weight Concentration of compound that gives half-maximal mcrease m decidual response (default-mg/kg) IC 50 for uterme weight Concentration of compound that gives half-maximal decrease m EC50 progesterone mduced decidual response (default-mg/kg) EXAMPLE 13 5-(2-,4-,4-Trimethyl-l--,4-dihvdro-2H-3-,l-beιιzoxazin-6-yl)thiophene-2-carbonitrile A solution of 2-ammo-5-bromobenzoιc acid (lOg, 46 mmol) m dry THF (200 mL) was treated at -78 °C under mtrogen with a solution of methylmagnesium bromide m ether (3 0 M, 90 mL, 270 mmol) The reaction mixture was slowly warmed to ambient temperature, kept stinmg for 48 hours under mtrogen and then poured mto a cold 0 5 N aqueous hydrochlonde solution (300 mL) The mixture was neutralized with aqueous 1 N sodium hydroxide solution and ethyl acetate (300 mL) was added The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x100 mL) The combmed orgamc layers were washed with brme and dπed (MgS0 ) After removal of solvent in vacuo, the residue was purified by a sdica gel flash column chromatography(hexane ethyl acetate/3 2) to give 2-(2-amιno-5- bromophenyl)propan-2-ol as off-white sohd (6g, 57%) p 62-63 °C, Η-NMR (CDC1 3 ) δ 7 19 (d, IH, J= 2 3 Hz), 7 12 (dd, IH, J= 8 4, 2 3 Hz), 6 51 (d, IH, J = 8 4 Hz), 4 70 (s, 2H), 1 82 (s, IH), 1 65 (s, 6H) To a solution of 2-(2-amιno-5-bromophenyl)propan-2-ol (27g, 125 mmol) m anhydrous toluene was added at ambient temperature under a blanket of mtrogen acetylaldehyde (10 5 mL, 187 mmol) After 10 mmutes, the mixture was passed through a pad of sihca gel and filtrate was concentrated to yield 6-bromo-2,4,4- tπmethyl-1.4-dιhydro-2H-3,l-benzoxazιne as off-white solid (25g, 78%) ] H-NMR (DMSO-< ) δ 7 22 (d, IH, J= 2 2 Hz), 7 08 (dd, IH, J= 8 6, 2 3 Hz), 6 51 (d, IH, J = 8 6 Hz), 6 36 (s, IH), 4 72 (m, IH), 1 45 (s, 3H), 1 40 (s, 3H), 1 25 (d, 3H, J= 5 5 Hz) A mixture of 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l-benzoxazme (3 6g, 14 mmol), bιs(pιnacolato)dιboron (5 g, 19 7 mmol), potassium acetate (4g, 41 mmol), and [l,l'-bis(diphenylphosphmo)ferrocene] palladium (II) chloride (1 1 complex with methylene chloride, 0 4g, 0 5 mmol) m DMF (80 mL) was subject to a positive nitrogen flow to remove oxygen and then heated at 85 °C under a blanket of mtrogen for 18 hours The mixture was allowed to cool to ambient temperature, treated with 5-bromo-2-thιophenecarbomtπle (4g, 21 mmol), [1,1 '- bιs(dιphenylphosphmo)fenocene] paUadium (II) chlonde (1 1 complex with methylene chlonde, 0 4g, 0 5 mmol), and aqueous sodium carbonate solution (2M, 35 mL, 70 mmol), and then heated at 85 °C under mtrogen for 3 hours The reaction mixture was allowed to cool to ambient temperature, brme (100 mL) and ethyl acetate (150 mL) were added The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x50 mL) The combined orgamc layers were dπed (MgS0 4 ) and concentrated The residue was purified by a flash sUica gel column chromatography(THF hexane/1 4) to afford the title compound as an off-white sohd (lg, 25%) mp 172-173 °C, ] H-NMR (DMSO--4) δ 7 88 (d, IH, J = 4 0 Hz), 7 47 (d, IH, J = 4 0 Hz), 7 43 (d, IH, J= 2 0 Hz), 7 32 (dd, IH, J = 8 36, 2 4 Hz), 6 77 (s, IH), 6 60 (d, IH, J= 8 4 Hz), 4 83 (m, IH), 1 51 (s, 3H), 1 48 (s, 3H), 1 28 (d, 3H, J = 5 6 Hz), MS (ESI) m/z 283 [M-H] " EXAMPLE 14 3-Fluoro-5-(2-A4-trimethyl-l,4-dihydro-2H-34-benzoxazin-6-yl)benzonitrile Prepared accordmg to the procedure for Example 13 from 6-bromo-2,4,4- tπmethyl-l,4-dιhydro-2H-3,l-benzoxazme and 3-bomo-5-fluorobenzomtπle A white sohd mp 163-164 °C, ] H-NMR (DMSO-af e ) δ 8 02 (t, IH, J - 1 5 Hz), 7 87 (dt, IH, J = 10 6, 2 2 Hz), 7 65 (m, IH), 7 55 (d, IH, J = 2 2 Hz), 7 44 (dd, IH, J= 8 4, 2 2 Hz), 6 63 (d, IH, J = 8 4 Hz), 6 58 (s, IH), 4 82 (m, IH), 1 52 (s, 3H), 1 50 (s, 3H), 1 28 (d, 3H, J= 5 1 Hz), MS (ESI) m/z 295 [M-H] EXAMPLE 15 4-(2.A4-Trimethyl-l,4-dihydro-2H-34-benzoxa-zin-6-yl)thiophene-2-carbonitrile Prepared accordmg to the procedure for Example 13 from 6-bromo-2,4,4- tπmethyl-l,4-dιhydro-2H-3,l-benzoxazme and 4-bromo-2-thιophenecarbomtπle An off-white sohd mp 175-176 °C, Η-NMR (DMSO- 6 ) δ 8 39 (d, IH, J= 1 5 Hz), 8 13 (d, IH, J= 1 5 Hz), 7 47 (d, IH, J = 1 9 Hz), 7 36 (dd, IH, J = 8 4, 1 9 Hz), 6 59 (d, IH, J= 8 4 Hz), 6 41 (s, IH), 4 78 ( , IH), 1 51 (s, 3H), 1 47 (s, 3H), 1 28 (d, 3H, J = 5 4 Hz), MS (ESI) m/z 285 [M+H] + EXAMPLE 16 4-Methyl-5-(2,4-,4-trimethyl-l-,4-dihvdro-2H-3,l-benzoxazin-6-yl)thiophene-2- carbonitrile Prepared accordmg to the procedure for Example 13 from 6-bromo-2,4,4- tπmethyl-l,4-dιhydro-2H-3,l-benzoxazme and 5-bromo-4-methyl-2- thiophenecarbomtπle A yeUowish solid mp 145-146 °C, Η-NMR (DMSO-- ) δ 7 79 (s, IH), 7 18 (d, IH, J= 2 0 Hz), 7 13 (dd, IH, J= 8 4, 2 0 Hz), 6 68 (s, IH), 6 54 (d, IH, J= 8 3 Hz), 4 83 (m, IH), 2 26 (s, 3H), 1 49 (s, 3H), 1 46 (s, 3H), 1 28 (d, 3H, J = 5 5 Hz), MS (ESI) m/z 299 [M+H] + EXAMPLE 17 3-r(2R.4S)-2.4-Dimethyl-4-phenyl-l-4-dihvdro-2H-3.1-benzoxazin-6-yll-5- fluorobenzonitrile To a solution of 2-ammo-4-bomobenzomtnle (5g, 25 mmol) m anhydrous THF, was added at 0 °C under mtrogen, phenylmagnesium bromide (3 M m ether, 25 mL, 75 mmol) The mixture was aUowed to warm to room temperature, stirred under nitrogen for 15 hours, and treated with 2N aqueous hydrogen chloride solution (100 mL) The aqueous solution was heated to 50 °C for 3 hours, cooled to room temperature, and neutralized with a cold saturated sodium bicarbonate solution Ethyl acetate (100 mL) was added and the orgamc layer was separated and aqueous layer was extracted with ethyl acetate (3x40 mL) The combmed orgamc layers were dried (MgS0 4 ) and evaporated The residue was purified by a flash column chromatography(sιlιca gel, hexane ethyl acetate/4 1) to yield (2-amιno-5- bromophenyl)(phenyl)methanone as a yellow crystal (2 13g, 31%) MS (ESI) m/z 2 '6/27 '8 [M+H] + To a solution of (2-ammo-5-bromophenyl)(phenyl)methanone (lg, 3 6 mmol) m anhydrous THF (15 mL) was added at room temperature under mtrogen methylmagnesium bromide (3M m ether, 3 mL, 9 mmol) After 3 hours, the mixture was treated with a saturated aqueous ammomum sulfate solution (30 mL) and ethyl acetate (50 mL) The orgamc layer was separated, dned (MgS0 4 ), and evaporated The residue was then dissolved m anhydrous toluene and treated at ambient temperature under nitrogen with acetylaldehyde (2 mL) After 2 mmutes, the solvent was removed and residue was purified by a column chromatography(sύιca gel, hexane ethyl acetate/4 1) to afford 6-bromo-2,4-dιmethyl-4-phenyl-l,4-dιhydro-2H- 3,1-benzoxazιne as a yeUowish sohd (0 8g, 70%) MS (ESI) m/z 318/320 [M+H] + A mixture of 6-bromo-2,4-dιmethyl-4-phenyl- 1 ,4-dιhydro-2H-3 , 1 -benzoxazme (0 6g, 1 9 mmol), 3-cyano-5-fluorobenzene boromc acid (0 45g, 2 7 mmol), tetrakιs(tπphenylphosphιne)palladιum (0) (0 2g, 0 17 mmol), sodium carbonate (0 6g, 5 7 mmol) m a mixture of DME and water (20/5 mL) was subject to a positive mtrogen flow to remove oxygen and then heated to 85 °C under a blanket of nitrogen for 2 hours The mixture was allowed to cool to ambient temperature Brme (30 mL) and ethyl acetate (100 mL) were added The orgamc layer was separated and aqueous layer was extracted with ethyl acetate (3x30 mL) The combined orgamc layers were dned (MgS0 ), and evaporated The residue was purified by a silica gel column chromatography(hexane ethyl acetate/4 1) to afford the title compound as off-white sohd (0 09g, 13%) mpl28-129 °C, Η-NMR (DMSO- 6 ) δ 8 08 (s, IH), 7 91 (dt, IH, J= 10 7, 1 9 Hz), 7 71 (d, IH, J= 2 0 Hz), 7 65 (m, IH), 7 57 (dd, IH, J= 8 8, 2 4 Hz), 7 32-7 36 (m, 2H), 7 24-7 29 (m, 3H), 6 71 (d, IH, J= 1 6 Hz), 6 69 (d, IH, J= 8 3 Hz), 4 33 (m, IH), 1 84 (s, 3H), 1 24 (d, 3H, J = 5 5 Hz), MS (ESI) m/z 357 [M-H] EXAMPLE 18 fe7t-Butyl 2-cvano-5-(2-A4-trimethyI-l,4-dihvdro-2H-34-benzoxazin-6-yl)-lH- pyrrole-1-carboxylate tert-Butyl-5-(2,4,4-tπmethyl-l,4-dιhydro-2H-3,l-benzoxazm-6-yl)-lH-pyrrole- 1-carboxylate was prepared accordmg to the couplmg procedure for Example 17 from 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l-benzoxazme and 1-t- butoxycarbonylpyrrol-2-yl boromc acid To a solution of tert-butyl-5-(2,4,4-tnmethyl- l,4-dιhydro-2H-3,l-benzoxazm-6-yl)-lH-pyrrole- 1-carboxylate (lg, 2 9 mmol) m anhydrous THF (20 mL) was added at -78 °C under mtrogen chlorosulfonyl lsocyanate (0 35 mL, 4 0 mmol) The mixture was kept stirrmg at -78 °C under nitrogen for 2 hours, treated with anhydrous DMF (5 mL), and allowed to warm to room temperature Aqueous ammomum sulfate solution (50 mL) and ethyl acetate (100 mL) was added and organic layer was separated, dried (MgS0 4 ), and evaporated The residue was purified by a silica gel column chromatography(hexane ethyl acetate/4 1) to afford the title compound as a white solid (0 019g, 1 78%) ] H-NMR (DMSO-- ) δ 7 48 (d, IH, J = 2 0 Hz), 7 36 (dd, IH, J= 8 3, 2 0 Hz), 7 32 (d, IH, J = 3 6 Hz), 7 14 (d, IH, J= 8 3 Hz), 6 46 (d, IH, J= 4 0 Hz), 5 35 (q, IH, J = 5 2 Hz), 1 58 (d, 3H, J= 5 6 Hz), 1 56 (s, 3H), 1 51 (s, 3H), 1 38 (s, 9H), MS (ESI) m/z 366 [M-H] EXAMPLE 19 9H-Fluoren-9-ylmethyl-6-fl-(tert-butoxycarbonyl)-5-cvano-lH-pyrrol-2-yll- 2,4,4-trimethyl-2H-3-,l-benzoxazine-l(4H)-carboxylate A mixture of tert-butyl-5-(2,4,4-tnmethyl-l,4-dιhydro-2H-3,l-benzoxazm-6- yl)-lH-pyrrole- 1-carboxylate (1 7g, 4 96 mmol), 9-fluorenylmethyl chloroformate (1 92g, 7 5 mL), sodium carbonate (4g, 37 mmol) m dioxane (50 mL) and water (50 mL) was stined at room temperature under a blanket of mtrogen for 6 hours Ethyl acetate (100 mL) was added and organic layer was separated, dried (MgS0 4 ), and evaporated The residue was puπfied by a sihca gel column chromatography(hexane ethyl acetate/6 1) to afford 9H-fluoren-9-ylmethyl-6-[l-(tert- butoxycarbonyl)-lH-pynol-2-yl]-2,4,4-tπmethyl-2H-3,l-benzoxazme-l(4H)- carboxylate as a clean oU Usmg the procedure for Example 18, the title compound (0 8g, 65%) was prepared from 9H-fluoren-9-ylmethyl-6- [ 1 -(tert-butoxycarbonyl)- 1 H-pynol-2-yl] - 2,4,4-tπmethyl-2H-3,l-benzoxazme-l(4H)-carboxylate (l 2g, 2 1 mmol) and chlorosulfonyl lsocyanate (0 28 mL, 3 1 mmol) A white sohd mp 135-136 °C, 'H- NMR (OMSO-d 6 ) δ 7 90 (t, 2H, J = 6 7 Hz), 7 64 (d, IH, J= 7 5 Hz), 7 59 (d, IH, J = 7 1 Hz), 7 40 (td, 2H, J= 7 2, 2 0 Hz), 7 31-7 34 ( , 3H), 7 29 (d, IH, J = 1 2 Hz), 7 04-7 09 (m, 2H), 6 44 (d, IH, J = 3 57 Hz), 5 30 (q, IH, J= 5 6 Hz), 4 86 (dd, IH, J= 10 7, 5 2 Hz), 4 64 (dd, IH, J = 10 8, 5 2 Hz), 4 33 (t, IH, J= 4 7 Hz) 1 50 (s, 3H), 1 30 (s, 9H), 1 20 (s, 3H), 1 03 (d, 3H, J= 5 6 Hz), MS (ESI) m/z 590 [M+H] + EXAMPLE 20 5-(2-,4,4-Trimethyl-l--,4-dihvdro-2H-3.,l-benzoxazin-6-yl)-lH-pyrrole-2- carbonitrile 9H-Fluoren-9-ylmethyl-6- [ 1 -(tert-butoxycarbonyl)-5 -cyano- 1 H-pynol-2-yl] - 2,4,4-tπmethyl-2H-3,l-benzoxazme-l(4H)-carboxylate (0 5g, 0 84 mmol) was heated under a blanket of mtrogen at 160 °C until gas evolution ceased After coolmg to room temperature, 9H-fluoren-9-ylmethyl-6-[5-cyano-lH-pyrrol-2-yl]-2,4,4-trimethyl- 2H-3,l-benzoxazιne-l(4H)-carboxylate was obtamed as a white sohd (0 4g, 97%) A solution of 9H-fluoren-9-ylmethyl-6-[5-cyano-lH-pyrrol-2-yl]-2,4,4- tπmethyl-2H-3,l-benzoxazme-l(4H)-carboxylate (0 lg, 0 2 mmol) m 20% pipeπdine m DMF (5 mL) was stirred at room temperature under nitrogen for 10 minutes The mixture was poured mto a saturated ammonium sulfate solution (30 mL) and extracted with diethyl ether (3x30 mL) The combmed organic layers were dried (MgS0 4 ) and evaporated The residue was purified by a silica gel column chromatography(hexane ethyl acetate/3 1 ) to afford the title compound as a white solid (0 03g, 56%) mp 201-202 °C, ] H-NMR DMSO-d 6 ) δ 12 27 (s, IH), 7 44 (d, IH, J = 2 1 Hz), 7 32 (dd, IH, J= 8 3, 1 1 Hz), 6 92 (dd, IH, J= 4 1, 2 6 Hz), 6 57 (d, IH, J = 8 3 Hz), 6 50 (dd, IH, J = 4 2, 2 6 Hz), 6 40 (s, IH), 4 77-4 80 (m, IH), 1 51 (s, 3H), 1 46 (s, 3H), 1 27 (d, 3H, J= 5 7 Hz), MS (ESI) m/z 266 [M-H] ' EXAMPLE 21 9H-Fluoren-9-ylmethyl 6-(5-cyano- 1-methyl- lH-pyrrol-2-yl)-2-,4.,4-trimethyl-2H- '3, -benzoxazine- 1 (4H)-carboxylate A mixture of 9H-fluoren-9-ylmethyl-6-[5-cyano-lH-pyrrol-2-yl]-2,4,4- tnmethyl-2H-3,l-benzoxazme-l(4H)-carboxylate (0 4g, 0 8 mmol) and potassium carbonate (1 5g) in anhydrous DMF was treated at ambient temperature under a blanket of nitrogen with lodomethane (1 5 mL, excess) The mixture was stined for 30 mmutes A saturated ammomum sulfate solution (50 mL) and ethyl acetate (50 mL) was added The orgamc layer was separated and aqueous layer was extracted with ethyl acetate (3x15 mL) The combmed orgamc layers were dned (MgS0 4 ), evaporated to yield the title compound as a white solid (0 35g, 87%) mp 63-64 °C, Η-NMR (OMSO-d 6 ) δ 7 90 (m, 2H), 7 62 (d, IH, J= 7 7 Hz), 7 58 (d, IH, J= 7 7 Hz), 7 40 (m, 2H), 7 29-7 32 (m, 3H), 7 14 (dd, IH, J = 8 1, 1 9 Hz), 7 01-7 04 (m, 2H), 6 33 (d, 1H, J = 4 3 Hz), 5 31 (q, IH, J= 5 8 Hz), 4 88 (dd, IH, J= 10 8, 5 0 Hz), 4 65 (dd, IH, J= 10 8, 4 6 Hz), 4 34 (t, IH, J= 4 6 Hz), 3 71 (s, 3H), 1 52 (s, 3H), 1 21 (s, 3H), 1 06 (d, 3H, J= 5 4 Hz), MS (ESI) m/z 504 [M+H] + EXAMPLE 22 l-Methyl-5-(2.4 < 4-trimethyl-l,4-dihydro-2H-3-,l-benzox-azin-6-yl)-lH-pyrroIe-2- carbonitrile Prepared accordmg to the procedure for Example 20 from 9H-fluoren-9- ylmethyl 6-(5 -cyano- 1 -methyl- 1 H-pynol-2-yl)-2,4,4-tπmethyl-2H-'3, 1 -benzoxazme- l(4H)-carboxylate (0 3g, 0 6 mmol) and 20% pipeπdme in DMF A white sohd (0 07g, 42%) mp 195-196 °C, ! H-NMR (OMSO-d 6 ) δ 7 16 (d, IH, J= 2 8 Hz), 7 08 (dd, IH, J = 8 1, 1 9 Hz), 6 98 (d, IH, J= 4 1 Hz), 6 63 (d, IH, J= 8 5 Hz), 6 61 (s, IH), 6 20 (d, IH, J = 4 1Hz), 4 79-4 81 (m, IH), 3 67 (s, 3H), 1 49 (s, 3H), 1 45 (s, 3H), 1 27 (d, 3H, J= 5 5 Hz), MS (ESI) m/z 282 [M+H] + EXAMPLE 23 5-(2-Methylspirof4-H-3,l-benzoxazine-4-,l'-cvclopentanel-6-yl)-4 methyl-2- thiophenecarbonitrile 2-Methyl-6-bromospιro[4H-3,l-benzoxazιne-4,l'-cyclopentane] was prepared usmg the same procedure as for 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l- benzoxazme m Example 13 The title compound was prepared accordmg to the procedure for Example 13 from 2-methyl-6-bromospιro[4H-3,l-benzoxazme-4,l'-cyclopentane] and 5-bromo-4- methyl-2-thιophenecarbomtπle A yeUowish solid mp 58-60 °C, Η-NMR (DMSO- d 6 ) b ! 19 (s, IH), 7 16 (d, IH, J = 1 9 Hz), 7 12 (dd, IH, J = 8 4, 2 2 Hz), 6 66 (s, IH), 6 63 (d, IH, J= 8 4 Hz), 4 75 (m, IH), 2 26 (s, 3H), 2 14 (m, IH), 1 87 (m, IH), 1 4-1 7 (m, 6H), 1 32 (d, 3H, J= 5 5 Hz) EXAMPLE 24 4-(2-Methylspiro[2H-3,l-benzoxazine-4, -cvclopentanel-6-yl)-2- thiophenecarbonitrile Prepared accordmg to the procedure for Example 13 from 2-methyl-6- bromospιro[4H-3,l-benzoxazιne-4,r-cyclopentane] and 4-bromo-2- thiophenecarbonitπle An off-white sohd mp 103-104 °C EXAMPLE 25 5-(2-methylspiro[2H-3,l-benzoxazine-4,r-cyclohexanel-6-yl)-4-methyl-2- thiophenecarbonitrile 2-Methyl-6-bromospιro [2H-3 , 1 -benzoxazιne-4, 1 '-cyclohexane] was prepared using the same procedure as for 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l- benzoxazme m Example 13 The title compound was prepared accordmg to the procedure for Example 13 from 2-methyl-6-bromospιro[4H-3,l-benzoxazme-4,r-cyclohexane] and 5-bromo-4- methyl-2-thιophenecarbomtπle A brown solid 'H-NMR (OMSO-d 6 ) δ 7 78 (s, IH), 7 17 (d, IH, J= 1 8 Hz), 7 14 (dd, IH, J = 8 4, 2 2 Hz), 6 64 (s, IH), 6 63 (d, IH, J = 8 2 Hz), 4 74 ( , IH), 2 26 (s, 3H), 2 14 (m, IH), 1 87 (m, IH), 1 4-1 7 (m, 8H), 1 31 (d, 3H, J= 5 3 Hz), MS (ESI) m/z 337 [M-H] " EXAMPLE 26 4-(2-Methylspiro[2H-3-,l-benzoxazine-4--,l'-cvclohexanel-6-yl)2- thiophenecarbonitrile Prepared accordmg to the procedure for Example 13 from 2-methyl-6- b omospιro[4H-3,l-benzoxazme-4,l'-cyclohexane] and 4-bromo-2- thiophenecarbomtnle A brown sohd mp 111-112 °C, Η-NMR (DMSO-c^) δ 8 42 (s, IH), 8 14 (s, IH), 7 47 (s, IH), 7 35 (dd, IH, J = 8 3, 1 1 Hz), 6 58 (d, IH, J = 8 4 Hz), 6 38 (s, IH), 4 72 (m, IH), 1 92-2 16 (m, 2H), 1 35-1 75 (m, 8H), 1 31 (d, 3H, J = 5 3 Hz), MS (ESI) m/z 325 [M+H] + EXAMPLE 27 6-(3-Fluorophenyl)-2,4-,4-trimethyl-l,4-dihvdro-2H-3,l-benzoxazine Prepared accordmg to the couplmg procedure for Example 17 from 3- fluorophenyl boromc acid and 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l- benzoxazine A yellow sohd mp 139-140°C, 'H-NMR (CDC1 3 ) δ 7 40-7 19 (m, 6H), 7 01-6 94 (m, IH), 6 72 (d, IH, J= 8 24 Hz), 4 90 (q, IH, J= 5 48 Hz), 1 62 (s, 3H), 1 59 (s, 3H), 1 46 (d, 3H, J= 5 5 Hz), MS (ES) m/z 272 ([M+H] + ) EXAMPLE 28 6-(3-Chlorophenyl)-2,4,4-trimethyl-l,4-dihvdro-2H-3.,l-benzoxazine Prepared accordmg to the couplmg procedure for Example 17 from 3- chlorophenyl boromc acid and 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l- benzoxazme A orange solid mp 144-146 °C, Η-NMR (CDC1 3 ) δ 7 50 (t, IH, J = 1 78 Hz), 7 40 (dt, IH, J= 7 61, 1 45 Hz), 7 33 (t. IH, J= 7 76 Hz), 7 29-7 22 (m, 4H) 6 72 (d, IH, J = 8 24 Hz), 4 90 (q, IH, J= 5 45 Hz), 1 62 (s, 3H), 1 59 (s, 3H), 1 4 6 (d, 3H, J= 5 5 Hz), MS (ES) m/z 288/290 ([M + H] + ) EXAMPLE 29 6-(3-Chloro-4-fluorophenyl)-2-,4--,4-trimethyl-l.,4-dihvdro-2H-3-,l-benzoxazine A mixture of 6-bromo-2,4,4-tπmethyl-l,4-dιhydro-2H-3,l -benzoxazine (3 0 g, 11 7 mmol), 3-chloro-4-fluorobenzeneboronιc acid (3 1 g, 17 6 mmol), tetrakιs(trιphenylphosphιne)paUadιum (0) (0 67 g, 0 59 mmol), and sodium carbonate (3 72 g, 35 1 mmol) m DME (80 mL) and water (40 mL) was subject to a blanket of nitrogen flow fo 15 mmutes at 50°C and then was heated at 85°C under mtrogen for 1 hour The reaction was cooled to room temperature and ethyl acetate (200 mL) was added The orgamc layer was washed twice with aqueous ammomum chloride (50 mL) and once with brme (50 mL), dned over sodium sulfate and concentrated to a yellow solid The solid was triturated with ether (25 mL) and hexane (25 mL), collected on a filter, and dried to give 6-(3-chloro-4-fluorophenyl)-2,4,4-tπmethyl-l,4- dιhydro-2H-3,l -benzoxazine (1 87 g, 35%) as ayellow solid mp 173-175°C, Η- NMR (DMSO-ύ δ 7 79 (dd, IH, J= 6 84, 2 14 Hz), 7 60-7 57 (m, IH), 7 43-7 39 (m, 2H), 7 29 (dd, IH, J = 8 12, 2 14 Hz), 6 62 (d, IH, J= 8 54 Hz), 6 40 (s, IH), 4 79 (q, IH, J= 5 55 Hz), 1 53 (s, 3H), 1 48 (s, 3H), 1 28 (d, 3H, J= 5 55 Hz), MS (ES) m/z 306/308([M + H] + ) EXAMPLE 30 2-Fluoro-5-(2-,4-,4-trimethyl-l,4-dihvdro-2H-3--ιl-benzoxazin-6-yl)benzonitrile Prepared accordmg to the couplmg procedure for Example 13 from 6-bromo- 2,4,4-tnmethyl- 1 ,4-dιhydro-2H-3 , 1 -benzoxazine and 5-bromo-2-fluorobenzomtnle A white solid mp 184-186°C, 5 H-NMR DMSO-d 6 ) δ 8 17 (dd, IH, J= 5 86, 3 42 Hz), 8 00-7 98 (m, IH), 7 52 (t, IH, J= 9 28 Hz), 7 45 (d, IH, J= 1 95 Hz), 7 34 (dd, IH, J= 8 30, 1 95 Hz), 6 63 (d, IH, J= 8 3 Hz), 6 45 (d, IH). 4 8 (q, IH, J= 5 37 Hz), 1 53 (s, 3H), 1 49 (s, 3H), 1 29 (d, 3H, J= 5 37 Hz), MS (ES) m/z 297 ([M + H] + ) EXAMPLE 31 4-(2,4,4-Trimethyl-l,4-dihydro-2H-3,l-benzoxazin-6-yl)-2-furonitrile Prepared usmg the coupling procedure for Example 13 from 6-bromo-2,4,4- tπmethyl-l,4-dιhydro-2H-3,l -benzoxazine and 4-bromo-2-cyanofuran A light brown sohd mp 116-118 °C, Η-NMR (OMSO-d 6 ) δ 8 43 (s, IH), 8 06 (s, IH), 7 38 (d, IH, J= 1 98 Hz), 7 25 (dd, IH, J= 7 93, 1 98 Hz) 6 58 (d, IH, J= 7 93 Hz), 6 37 (s, IH), 4 77 (q, IH, J= 5 55 Hz), 1 50 (s, 3H), 1 46 (s, 3H), 1 27 (d, 3H, J= 5 55 Hz), MS (ES) m/z 269 ([M+H] + ), Anal Calc For Cι 6 H 16 N 2 0 2 C, 71 62, H, 6 01, N, 10 44 Found C, 71 55, H, 6 26, N, 10 17 EXAMPLE 32 3-[4-,4-Dimethyl-2-(trifluoromethyl)-l-,4-dihvdro-2H-3,l-benzoxazin-6-yll-5- fluorobenzonitrile A mixture of 2-(2-ammo-5-bromo-phenyl)-propan-2-ol (5 g, 21 7 mmol), tπfluoroacetaldehyde methyl hemiacetal (5 mL), and magnesium sulfate (10 g) m toluene (75 mL) was heated at 80°C under mtrogen After disappearance of the starting material, the reaction was filtered through a pad of silica gel and the filtrate dned over sodium sulfate and concentrated to give 6-bromo-4,4-dιmethyl-2- (tnfluoromethyl)-l,4-dihydro-2H-3,l-benzoxazme as an amorphous sohd Η-NMR (OMSO-d 6 ) δ 7 31 (d, IH, J= 1 99 Hz), 7 19 (dd, IH, J= 8 73, 2 38 Hz), 6 88 (s IH), 6 74 (d, IH, J= 8 33 Hz), 5 32 (m, IH), 1 52 (s, 6H) A mixture of 6-bromo-4,4-dιmethyl-2-(tπfluoromethyl)- 1 ,4-dιhydro-2H-3 , 1 - benzoxazme (0 5 g, 1 61 mmol), 3-cyano-5-fluorobenzeneboromc acid (0 39 g, 1 8 mmol), tetrakis(triphenylphosphme)-paUadium (0) (0 2 g, 0 161 mmol), and sodium carbonate (0 5 g, 4 83 mmol) in DME (50 mL) and water (25 mL) was subject to a blanket of mtrogen flow for 15 minutes at 50°C and then was heated at 85°C under nitrogen for 1 hour The reaction mixture was cooled to room temperature and ethyl acetate (200 mL) was added The orgamc layer was washed twice with aqueous ammomum chloride (20 mL) and once with brme (20 mL), dned over sodium sulfate and concentrated to ayeUow solid Purification via flash column chromatography (silica gel, 5% ethyl acetate/hexane) gave 3-[4,4-dιmethyl-2-(tπfluoromethyl)-l,4- dιhydro-2H-3,l-benzoxazm-6-yl]-5-fluorobenzomtπle (0 396 g, 73%) as a white sohd mp 102-103°C, Η-NMR (OMSO-d 6 ) δ 8 07 (s, IH), 7 91 (d, IH, J= 10 7 Hz), 7 7 (d, lH, J= 10 7 Hz) 7 62 (d, 1H, J= 1 98 Hz), 7 53 (dd, 1H, J= 8 33, 1 98 Hz), 7 05 (s, IH), 6 87 (d, IH, J= 8 33 Hz), 5 39-5 37 (m, IH), 1 61 (s, 3H), 1 59 (s, 3H), MS (ES) m/z 349 ([M-H] ) EXAMPLE 33 4-[4,4-Dimethyl-2-(trifluoromethyl)- 4-dihvdro-2H-3,l-benzoxaz-in-6- yll thiophene-2-carbonitrile Prepared usmg the couplmg procedure for Example 13 starting with 6-bromo- 4,4-dιmethyl-2-(tπfluoromethyl)-l,4-dιhydro-2H-3,l-benzoxazme and 4-bromo-2- thiophenecarbonitπle A yellow solid Η-NMR (DMSO-d 6 ) δ 8 43 (s, IH), 8 19 (s, IH), 7 54 (d, IH, J= 1 98 Hz), 7 46 (dd,lH, J= 8 33, 1 98 Hz), 6 90 (s, IH), 6 83 (d, IH, J= 8 33 Hz), 5 35 (d, IH, J= 3 57 Hz), 1 59 (s, 3H), 1 57 (s, 3H), MS (ES) m/z 337 ([M-H] ) EXAMPLE 34 4-H-Acetyl-4-,4-dimethyl-2-(trifluoromethyl)-l--,4-dihvdro-2H-3-,l-benzoxazin-6- yllthiophene-2-carbonitrile 4-[4,4-dιmethyl-2-(tnfluoromethyl)-l ,4-dιhydro-2H-3, l-benzoxazm-6- yl]thιophene-2-carbomtnle (0 25 g, 0 74 mmol) was dissolved m DMF (10 mL), NaH (0 09 g, 2 22 mmol) was added and the mixture was stined for 30 mmutes pπor to the addition of acetyl chloride (0 079 mL, 1 11 mmol) Upon disappearance of the startmg material the reaction mixture was poured mto brme (100 mL) and the product extracted with ether (150 mL), dried over sodium sulfate and concentrated The residue was purified by a flash column chromatography (sihca gel, 25% ethyl acetate/hexane) to yield 4-[l-acetyl-4,4-dιmethyl-2-(tπfluoromethyl)-l,4-dιhydro-2H- 3,l-benzoxazm-6-yl]thιophene-2-carbomtnle (0 1 g, 36%) as an amorphous solid Η- NMR (DMSO-- ) δ 8 58 (s, IH), 8 5 (s, IH), 7 83-7 80 (m, 2H), 7 64 (d, IH, J = 8 74 Hz), 6 42 (q, IH, J= 10 Hz), 2 24 (s, 3H), 1 73 (s, 3H), 1 42 (s, 3H) EXAMPLE 35 (6(5-Cvanothien-3-yl)-4--,4-dimethyl-2-(trifluoromethyl)-2H-3 -benzoxazin- l(4H)-yl)methyl pivalate 4-[4,4-dιmethyl-2-(tπfluoromethyl)-l ,4-dιhydro-2H-3, l-benzoxazm-6- yl]thιophene-2-carbonιtπle (0 30 g, 0 89 mmol) was dissolved m DMF (10 mL), NaH (0 065 g, 2 7 mmol) was added and the was mixture stirred for 30 mmutes prior to the addition of tert-butyl chloroacetate (0 19 mL, 1 3 mmol) Upon disappearance of the startmg material the reaction mixture was poured mto brme (100 mL) and the product extracted with ether (150 mL), dried over sodium sulfate and concentrated Flash column chromatography (silica gel, 8% ethyl acetate/hexane) gave (6(5-cyanothιen-3- yl)-4,4-dιmethyl-2-(tπfluoromethyl)-2H-3 , 1 -benzoxazm- 1 (4H)-yl)methyl pivalate (0 127 g, 32%) as an amorphous sohd 1H-NMR (CDC1 3 ) δ 7 82 (s, IH), 7 58 (s, IH), 7 41 (dd, 1H, J = 8 33, 1 98 Hz), 7 25 (d, lH, J= 1 98 Hz) 7 10 (d, lH, J= 8 33 Hz), 6 79 (d, lH, J= 8 33 Hz), 5 66 (d, lH, J= 11 9 Hz), 5 38 (d, 1H, J= 11 9 Hz), 1 72 (s, 3H), 1 55 (s, 3H), 1 18 (s, 9H) EXAMPLE 36 3-Fluoro-5-(2--,2-,4--,4-tetramethyl-l-,4-dihvdro-2H-3-,l-benzoxazin-6-yl)benzonitrile Prepared usmg the couplmg procedure for Example 13 startmg with 6-bromo- 2,2,4,4-tetramethyl-l,4-dιhydro-2H-3,l -benzoxazine and 3-bromo-5- fluorobenzomtπle A white sohd Η-NMR DMSO-d 6 ) δ 8 03 (s, IH), 7 87 (d, IH, J = 10 7 Hz), 7 65 (d, IH, J= 10 7 Hz), 7 57 (d, IH, J= 1 98 Hz) 7 45 (dd, IH, J = 8 33, 1 98 Hz), 6 65 (d, IH, J= 8 33 Hz), 6 42 (s, IH), 1 52 (s, 6H), 1 34 (s, 6H), MS (ES) m/z 311 ([M+H] + ) EXAMPLE 37 4-(2-,2-,4-,4-Tetramethyl-l-,4-dihvdro-2H-3,l-benzoxazin-6-yl)thiophene-2- carbonitrile Prepared usmg the couplmg procedure for Example 13 startmg with 6-bromo- 2,2,4,4-tetramethyl-l,4-dιhydro-2H-3,l -benzoxazine and 4-bromo-2-cyanothιophene An amorphous orange sohd Η-NMR (DMSO- 6 ) δ 8 4 (d, IH, J = 1 69 Hz), 8 14 (d, IH, J = 1 69 Hz), 7 49 (d, IH, J= 2 20 Hz), 7 38 (dd, IH, J= 8 43, 2 02 Hz), 6 61 (d, IH, J= 8 43 Hz), 6 26 (s, IH), 1 49 (s, 6H), 1 32 (s, 6H), MS (ES) m/z 299 ([M+Hf) EXAMPLE 38 5-[4-,4-Dimethyl-2-(trifluoromethyl)-l-,4-dihvdro-2H-3 -benzoxazin-6-yll-4- methylthiophene-2-carbonitrile Prepared according to the coupling procedure for Example 13 from 6-bromo- 4,4-dιmethyl-2-(tπfluoromethyl)- 1 ,4-dιhyd o-2H-3 , 1 -benzoxazme and 5-bromo-4- methyl-2-thιophene-carbonιtπle A yeUowish sohd mp 97-98 °C, Η-NMR (DMSO- d 6 ) δ 7 82 (s, IH), 7 26 (d, IH, J = 1 7 Hz), 7 21 (dd, IH, J = 8 1, 2 1 Hz), 7 16 (s. 1H), 6 88 (d, IH, J = 8 1 Hz), 5 40 (m, IH), 2 27 (s, 3H), 1 56 (s, 3H), 1 55 (s, 3H), MS (ESI) m/z 351 [M-H] EXAMPLE 39 6-r3-Chlorophenyl)-4-,4-dimethyl-2-(trifluoromethyl)-l-,4-dihvdro-2H-3.1- benzoxazine Prepared according to the couplmg procedure for Example 17 from 6-bromo- 4,4-dιmethyl-2-(tπfluoromethyl)-l,4-dιhydro-2H-3,l-benzoxazme and 3-chlorophenyl boromc acid A yeUowish solid mp 108-109 °C, Η-NMR (DMSO-- ) δ 7 69 (t, IH, J = 1 7 Hz), 7 59 (d, IH, J = 7 8 Hz), 7 35-7 50 (m, 3H), 7 32 (dt, IH, J = 8 1, 1 1 Hz), 6 91 (s, IH), 6 87 (d, IH, J = 8 4 Hz), 5 35 (m, IH), 1 60 (s, 3H), 1 59 (s, 3H), MS (ESI) m/z 340 [M-H] EXAMPLE 40 6-(3-Fluorophenyl)-4,4-dimethyl-3,4-dihydroquinolin-2(lH)-one Prepared by couplmg 3-fluorophenylboronιc acid with an equivalent amount of 6-bromo-4,4-dιmethyl-3,4-dιhydo-lH-qumolm-2-one usmg a catalytic amount of tetrakis(triphenylphosphme)paUadium(0) with overnight refluxing m toluene contaimng an equivalent amount of potassium carbonate dissolved m water Work up m the usual manner followed by recrystallization from ethanol gave a grey sohd mp 190-192° C 'H-NMR (DMSO--4) δ 10 27 (s, IH), 7 57 (s, IH), 7 50 (m, 4H), 7 15 (m, IH), 6 95 (d, IH J = 8 2Hz), 2 39 (s, 2H), 1 29 (s, 6H), MS (APCI (-)) m/z 268 [M-H] Anal Calc For Cι 7 Hι 6 FNO 0 25 H 2 0 C, 74 57, H, 6 07, N, 5 12 Found C, 74 86, H, 5 97, N 5 06 EXAMPLE 41 3-(4-,4-Dimethyl-2-oxo-l-,2-,3-,4-tet-rahvdroquinolin-6-yI)-5-fluorobenzonitrile 6-bromo-4,4-quιnolιn-2-one was aUowed to couple with an equivalent of bιs(pιnacolato)dιboron m refluxmg DMF containmg an equivalent of sodium carbonate dissolved m a minimal amount of water and a catalytic quantity of tetrakιs(tπphenylphosphιne)paUadιum(0) After refluxmg overnight an equivalent of 3- bromo-5-fluorobenzonιtπle was added Another equivalent of sodium carbonate was then added, followed by an additional amount of the same catalyst After several hours of reflux, the reaction mixture was filtered and taken to dryness m vacuo The residue was extracted mto ethyl acetate and the solution was dned over magnesium sulfate, filtered and the filtrate was again roto-evaporated to give a solid residue Recrystallization from ethanol afforded the title compound as a grey sohd mp 249- 250° C 'H-NMR (DMSO-< ) δ 10 32.(s, IH), 8 09 (t, IH, J= 1 6Hz), 7 93 (d, IH, J = 12 7 Hz) 7 77, (d, IH, J= 8 1Hz), 7 70 (s, IH), 7 61(d, IH J= 8 9Hz), 6 95 (d, IH, J = 8 3Hz),2 40 (s, 2H), 1 30 (s, 6H), MS (APCI (-)) m/z 293 [M-H] Anal Calc For C 18 H 15 FN 2 0 1 5H 2 0 C, 67 28, H, 5 65, N, 8 72 Found C, 67 36, H, 4 90, N s8 44 EXAMPLE 42 3-(4,4-Dimethyl-2-oxo-l,2 . . 4,-tetrahvdroquinolin-6-yl)benzonitri.e Prepared by couplmg 3-cyanophenylboromc acid with an equivalent amount of 6-bromo-4,4-dιmethyl-3,4-dιhydo-lH-qumolm-2-one usmg a catalytic amount of tetrakιs(tπphenylphosphme)paUadιum(0) as a catalyst with overnight refluxmg in toluene contaimng an equivalent amount of potassium carbonate dissolved in water in the usual manner followed by recrystallization from ethanol gave a grey solid mp 190 - 192 ° C, Η-NMR DMSO-d 6 ) δ 10 29 (s,lH), 8 17 (s, IH), 8 00 (d,lH, J = 7 9 Hz), 7 77 (d, IH, J = 6 4Hz), 7 65 (m, 2H), 7 55 (d, IH, J = 8 2 Hz), 6 97 (d, IH, J = 8 3 Hz), 2 40 (s, 2H), 1 30 (s, 6H), MS (APCI (-)) m/z 275 [M-H] " Anal Calc For Cι 8 Hι 6 N 2 0 0 25H 2 0 C, 75 77, H, 6 01, N, 9 82 Found C, 75 45, H, 5 65, N 9 20 EXAMPLE 43 6-(3-Chlorophenyl)-4,4-dimethyl-3,4-dihydroquinoline-2(lH)-thione Prepared by heatmg under reflux overnight a mixture of 6-(3-chlorophenyl)- 4,4-dιmethyl-3,4-dιhydroquιnolme-2(lH)-one and an equal weight of phosphorus pentasulfide m pyndme was stined Removal of the pyπdine in vacuo foUowed by treatmg the residue with 6N hydrochloπc acid and recrystaUization of the residue m ethanol gave the product as a yellow sohd mp 197 - 198° C : H-NMR (OMSO-d 6 ) δ 12 34 (s, IH), 7 75 (m, IH), 7 64 (m, 2H), 7 57 (dd , IH J= 9 3 and 2 1 Hz), 7 48 (t, IH, J= 1 7 Hz), 7 41 (m, 1H),7 20 (d, IH, J= 8 3 Hz), 3 34 (s, 2H), 1 26 (s,6H), MS (APCI (-)) m/z 300 [M-H] Anal Calc For C, 7 H 16 C1NS C, 67 65, H, 5 34, N, 4 64 Found C, 67 77, H, 5 57, N 4 54 EXAMPLE 44 6-(3-Fluorophenyl)-4,4-dimethvI-3,4-dihvdroquinoline-2(lH)-thione Prepared by heatmg under reflux overnight a mixture of 6-(3-fluororophenyl)- 4,4-dιmethyl-3,4-dιhydroqumohne-2(lH)-one and an equal weight of phosphorus pentasulfide was stirred m pyndme Workup as m the previous example gave a yellow sohd, mp 209-211° C Η-NMR (DMSO-- ) δ 12 34 (s,lH), 7 65 (d,lH J=2 2 Hz ) 7 57 (dd ,1H J ; = 8 24 J 2 = 2 2Hz), 7 51(m,3H), 7 18(m,2H), 2 84(s,2H), 1 26(s,6H) MS m/z 284 [M-H] " Anal Calc For d 7 H 16 FlNS C,71 55, H,5 65, N,4 91 Found C,71 18, H.5 59 N4 82 EXAMPLE 45 3-( 4,4-Dimethyl-2-thioxo- 1 -,2,3,4..-tetrahvd roq uinolin-6-yl) benzonitrile Prepared by heatmg under reflux overnight a stirred mixture of 3-(4,4- dιmethyl-2-oxo-l,2,3,4,-tetrahydroqumohn-6-yl)benzomtπle and an equal weight of phosphorus pentasulfide m pyndine and workup as m the previous example gave a yellow sohd mp 220-223 ° C dec Η-NMR DMSO-d 6 ) δ 12 35 (s, IH), 8 21 (s, IH), 8 10 (d, IH, J= 6 0 Hz), 7 80 (d, IH, J= 7 9Hz), 7 72 (s, IH), 7 65 (m, 2H), 7 21 (d, IH, J= 8 4 Hz), 2 85 (s, 2H), 1 27 (s, 6H), MS (APCI (-)) m/ ~ 2 < >1 [M-H] " Anal Calc For C, 8 H 16 N 2 S 3H 2 0 C, 62 40, H, 6 40, N, 8 09 Found C, 62 12, H, 4 88, N 7 77 EXAMPLE 46 3-(4-,4-Dimethyl-2-thioxo-l--,2-,3-,4-tetrahvdroquinolin-6-yl)-5-fluorobenzonitrile Prepared by heatmg under reflux overnight a stirred mixture of 3 -(4, 4- dιmethyl-2-oxo-l,2,3,4-tetrahydroqumohn-6-yl)-5-fluorobenzomtnle and an equal weight of phosphorus pentasulfide m pyndine and workup as m the previous example gave a yellow sohd mp 240-242° C dec , Η-NMR (DMSO-tt 6 ) δ 12 37 (s, IH), 8 13 (s, IH), 7 98 (dt,lH, j = 10 4 and 5 4 Hz), 7 81 (d, IH, j = 8 4Hz), 7 7 (d, IH, J = 1 8Hz), 7 68 (dd, IH, J = 8 3 and 1 9 Hz), 7 22 (d, IH, J = 8 3Hz), 2 85 (s, 2H), 1 27 (s, 6H), MS m/z 309 [M-H] Anal Calc For C, 8 H 15 FN 2 S 0 10 H 2 O C, 69 25, H, 4 91, N, 8 97 Found C, 69 15, H, 4 74, N 8 75 EXAMPLE 47 6-(3-Fluoro-phenyl)-2,4,4-trimethyl-l,2,3,4-tetrahvdro-quinoline 6-Bromo- 1 -(4-methoxy-benzyl)-4.4-dιmethyl-3.4-dιhydro- 1 H-quιnolιn-2-one To a solution of 6-bromo-4,4-dιmethyl-3,4-dιhydro-lH-qumolm-2-one (0 5g, 1 97mmol) in THF (25mL) was added 60% NaH (0 12g, 2 95mmol) suspended m mmeral oil The resultmg reaction mixture was stirred at room temperature for 30 mm , 4-methoxybenzyl chlonde (0 34g, 2 17) added, and heated under reflux for 20 h The reaction was cooled to room temperature then quenched slowly with water After extraction with ethyl acetate, the organic layer was dried (MgS0 4 ), evaporated and the residue purified by chromatography (Sι0 2 3 7 ethyl acetate/hexane) The white crystalline product was obtamed (0 35g, 48%), mp 118-119 °C, 'H NMR (OMSO-d 6 ) δ 1 23 (s, 6H), 2 59 (s, 2H), 3 70 (s, 3H), 3 72 (s, IH), 4 41 (d, IH, J= 5 86Hz), 5 09 (s, IH), 6 87 (m, 2H), 7 01 (d, IH, J= 8 78Hz), 7 17 (d, IH, J= 8 98Hz), 7 23 (d, IH, J= 8 79), 7 34 (dd, IH, J= 6 59 and 2 2 Hz), 7 43( d, IH, J= 2 2Hz), MS (APCI (+)) [M+H] + =374/376 6-(3-Fluoro-phenyl)-l-(4-methoxy-benzyl)-4.4-dimethyl-3.4-dihydro-lH-qumolm-2- one A mixture of 6-Bromo-l-(4-methoxy-benzyl)-4,4-dιmethyl-3,4-dιhydro-lH- quιnolιn-2-one (2 9g, 7 75mmol) in ethylene glycol dimethyl ether (50mL), K 2 C0 3 ( 1 18 g, 8 53mmol) m H 2 0 (5 OmL), and a catalytic amount of tetrakistriphenylphosphme paUadium was heated under reflux overnight After coolmg to room temperature, the mixture was extracted with ethyl acetate and the orgamc phase was washed with NaHC03 solution, brme, dried over MgS0 , concentrated, and crystaUized from ethanol to obtain the product as a white crystalline material (1 8 g, 60%) mp 159 - 162 °C, Η NMR (DMSO-ύ? 6 ) δ 1 32 (s, 6H), 2 63 (s, 2H ), 3 70 (s, 3H), 5 15 (s, 2H), 6 89 (d, 2H, J= 11 72Hz), 7 14 (m, 2H), 7 22 (d, 2H, J= 8 8Hz), 7 53 (m, 4H), 7 60 (d, IH, J= 2 2Hz), MS (APCI (+)) [M+H] + = 390 6-Bromo-l-(4-methoxy-benzyl)-2.4.4-t-πmethyl-1.4-dιhydro-qumolme To a solution of 6-(3-Fluoro-phenyl)-l-(4-methoxy-benzyl)-4,4-dunethyl-3,4- dιhydro-lH-qumolm-2-one (1 16g, 2 99mmol) m THF (15mL) at room temperature was added a solution of 1 4 M MeMgBr (2 6mL, 12 56mmol) and the resulting reaction mixture was stined for 6h The solution was quenched with H 2 0, extracted with EtOAc, treated with ammomum chloride solution, washed with brme, dried over MgS0 4 , and concentrated The product was purified by column chromatography using a 2 8 hexane/ethyl acetate mixtu e and used below To a solution of 6-(3-Fluoro-phenyl)-l-(4-methoxy-benzyl)-2,4,4-tπmethyl- 1,2,3,4-tetrahydroquιnohne (0 15g, 0 39mmol) m EtOH (35mL) was added 10%Pd/C and hydrogenated for 10 h at 40 psi The catalyst was removed by filtration through cehte and the product purified by chromatography A reddish hqmd was obtamed ] H NMR (OMSO-d 6 ) δ 1 15 ( d, 3H, J= 6 73Hz), 1 21( s, 3H ), 1 34(m, 4H), 1 60( dd, IH, J, =10 1,J 2 = 2 69, Hz), 3 40( m, IH), 5 95( s, IH), 6 55( d, IH, J= 8 08Hz), 7 01 ( m, IH), 7 21 (dd, IH, J =5 78 J 2 = 2 02 Hz), 7 35(m,4H), MS( FI Pos) [M+H] + =270 StiU other compounds, mcludmg 5-(2,4,4-Tπmethyl-l,2,3,4-tetrahydro- qumolm-6-yl)-lH-pynole-2-carbomtπle, l-Methyl-5-(2,4,4-tπmethyl-l,2,3,4- tetrahydro-qumolm-6-yl)-lH-pynole-2- carbomtnle , and 3-Fluoro-5-(2,4,4-tnmethyl- l,2,3,4-tetrahydro-qumolm-6-yl)-benzomtπle may be prepared usmg the methods described above AU publications cited m this specification are incorporated herem by reference herem While the mvention has been described with reference to a particularly prefened embodiment, it wiU be appreciated that modifications can be made without departing from the spint of the mvention Such modifications are mtended to fall within the scope of the appended claims

Claims: What is Claimed: 1 A method of contraception which compnses admimstenng to a female of chdd bearing age for 28 consecutive days a) a first phase of from 14 to 24 daily dosage units of a progestational agent equal m progestational activity to about 35 to about 100 μg levonorgestrel, b) a second phase of from 1 to 11 daUy dosage units, at a daily dosage of from about 2 to 50 mg, of an antiprogestm compound of Formula I I wherem R 1 , R 2 are mdependent substituents selected from the group which mcludes H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocychc alkyl rmg, b) an optionally substituted 3 to 8 membered spirocychc alkenyl, or c) an optionally substituted 3 to 8 membered heterocychc rmg contaimng one to three heteroatoms from the group mcludmg O, S and N, the spirocychc rmgs of a), b) and c) bemg optionally substituted by from 1 to 4 groups selected from fluorine, Ci to C 6 alkyl, Ci to C 6 alkoxy, Ci to C 6 thioalkyl, -CF 3 , -OH, - CN, NH 2 , -NH(C, to C 6 alkyl), or -N(C, to C 6 alkyl) 2 , R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, COR c , R c is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, R 4 is H, halogen, CN, N0 2 , C, to C 6 alkyl, substituted Ci to C 6 alkyl, alkynyl, or substituted alkynyl, Ci to C 6 alkoxy, substituted Ci to C 6 alkoxy, amino, Ci to C 6 ammoalkyl, substituted Ci to C 6 aminoalkyl, R 5 is selected from a) or b): a) R 5 is a trisubstituted benzene of the structure: X is taken from the group including halogen, CN, Ci to C 3 alkyl, substituted d to C 3 alkyl, alkynyl, or substituted alkynyl,Cι to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, amino, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 or 6 membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D ; R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, d to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted C, to C 3 aminoalkyl; R E is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl; Y and Z are independent substituents taken from the group including H, halogen, CN, N0 2 , amino, aminoalkyl, Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy; or b) R 5 is a five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, S0 2 or NR 6 and containing one or two independent substituents selected from H, halogen, CN, N0 2 , amino, and Ci to C 3 alkyl, Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, COR F , orNR G COR F ; R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl; R G is H, C, to C 3 alkyl, or substituted Ci to C 3 alkyl; R 6 is H or C, to C 3 alkyl; G 2 is CO or CR 7 Rs; provided that when G, is O, G 2 is CR 7 R 8 , and Gi and G 2 cannot both be CR 7 Rs; R 7 and Rs are independently selected from H or an optionally substituted alkyl, aryl, or heterocychc moiety; or pharmaceutically acceptable salt thereof; and c) optionaUy, a third phase of daily dosage units of an orally and pharmaceuticaUy acceptable placebo for the remaining days of the 28 consecutive days in which no antiprogestin, progestin or estrogen is administered; wherein the total daily dosage units of the first, second and third phases equals 28. 2. A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound has the structure: I wherem R 1 is H, C] to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, COR A , or NR B COR A , R 2 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form an optionally substituted 3 to 8 membered spirocychc alkyl, alkenyl or heterocychc rmg containmg one to three heteroatoms from the group mcludmg O, S and N, the spirocychc alkyl, alkenyl or heterocyc c rmgs bemg optionally substituted by from 1 to 4 groups selected from fluorine, Ci to Cβ alkyl, C, to C 6 alkoxy, Ci to C 6 thioalkyl, -CF 3 , -OH, -CN, NH 2 , -NH(C, to C 6 alkyl), or -N(Cι to C 6 alkyl) 2 , R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 ammoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted C, to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, COR c , R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted aryl, Ci to C 4 alkoxy, substituted Ci to C 4 alkoxy, Ci to C 4 ammoalkyl, or substituted Ci to C 4 ammoalkyl, R 4 is H, halogen, CN, N0 2 , C, to C 6 alkyl, substituted C, to C 6 alkyl, C, to C 6 alkoxy, substituted Ci to C 6 alkoxy, ammo, Ci to C 6 ammoalkyl, substituted Ci to C 6 ammoalkyl, a) R 5 is a benzene rmg of the structure X is selected from halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, ammo, Ci to C 3 ammoalkyl, substituted Ci to C 3 ammoalkyl, N0 2 , Ci to C perfluoroalkyl, 5 membered heterocyclic ring containmg 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 aminoalkyl, R E is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, Y and Z are independent substituents taken from the group including H, halogen, CN, N0 2 , Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy; or b) R 5 is a five or six membered ring with 1, 2, or 3 heteroatoms selected from the group of O, S, SO, S0 2 or NR 6 and containing one or two independent substituents selected from H, halogen, CN, N0 2 , amino, and Ci to C 3 alkyl, Ci to C 3 alkoxy; R 6 is H, or Ci to C 3 alkyl. G 2 is CO or CR 7 R 8 ; provided that when Gi is O, G 2 is CR 7 R 8 , and G, and G 2 cannot both be CR Rs; R 7 and Rs are independently selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, or substituted heterocychc; or a pharmaceutically acceptable salt thereof. 3. A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound has the structure: wherem R 1 = R 2 and are selected from Ci to C 3 alkyl, substituted Ci to C 3 alkyl, or spirocychc alkyl constructed by fusmg R 1 and R 2 to form a 3 to 6 membered spirocychc rmg, the spirocychc ring bemg optionaUy substituted by from 1 to 4 groups selected from fluonne, Ci to C 6 alkyl, Ci to C 6 alkoxy, Ci to C 6 thioalkyl, -CF 3 , -OH, - CN, NH 2 , -NH(C, to C 6 alkyl), or -N(C, to C 6 alkyl) 2 , R 3 is H, OH, NH 2 , d to C 6 alkyl, substituted C, to C 6 alkyl, -COH, -CO(C, to C 4 alkyl) or-CO(Cι to C 4 alkoxy), R 4 is H, halogen, N0 2 , Ci to C 3 alkyl, substituted C, to C 3 alkyl, X is taken from the group mcludmg halogen, CN, Ci to C 3 alkoxy, Ci to C3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocychc πng containmg 1 to 3 heteroatoms, Ci to C 3 thioalkoxy, Y is a substituent on the 4' or 5' position from the group mcludmg H, halogen, CN, N0 2 , Ci to C 3 alkoxy, Ci to C 4 alkyl, Ci to C 3 thioalkoxy G 2 is CO or CR 7 Rs; provided that when G, is O, G 2 is CR 7 Rs, and G, and G 2 car ot both be CR 7 Rs; wherein R 7 and Rs are independent substituents selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocychc, or substituted heterocychc; or pharmaceutically acceptable salt thereof 4. A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound has the structure: wherein: R 1 = R 2 and are selected from Ci to C 3 alkyl, substituted Ci to C 3 alkyl, or spirocycUc alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocyclic ring, the spirocychc ring being optionaUy substituted by from 1 to 4 groups selected from fluorine, Ci to C 6 alkyl, Ci to C 6 alkoxy, Ci to C 6 thioalkyl, -CF 3 , -OH, - CN, NH 2 , -NH(d to C 6 alkyl), or -N(C, to C 6 alkyl) 2 ; R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted C, to C 6 alkyl, -COH, -CO(C, to C 4 alkyl) or-CO(Cι to C 4 alkoxy); R 4 is H, halogen, N0 2 , C, to C 3 alkyl, substituted C, to C 3 alkyl; U is O, S, orNR 6 , R 6 is H, or C, to C 3 alkyl, d to C 4 C0 2 alkyl, X' is from the group including halogen, CN, N0 2 , Ci to C 3 alkyl and Ci to C 3 alkoxy; Y' is from the group including H and Ci to C 4 alkyl; G 2 is CO or CR 7 Rs; provided that when G, is O, G 2 is CR 7 R 8 , and G, and G 2 cannot both be CR 7 Rs; wherein R 7 and R 8 are independent substituents selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocychc, or substituted heterocychc; or pharmaceutically acceptable salt thereof 5. A method of Claim 1 wherein the progestational agent is levonorgestrel and the anti-progestin compound has the structure: wherein: R 1 = R 2 and are selected from Ci to C 3 alkyl, substituted Ci to C 3 alkyl, or spirocychc alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocycUc ring, the spirocyclic rings of being optionally substituted by from 1 to 4 groups selected from fluorine, Ci to C 6 alkyl, Ci to C 6 alkoxy, Ci to C 6 thioalkyl, -CF 3 , -OH, -CN, NH 2 , -NH(C, to C 6 alkyl), or -N(C, to C 6 alkyl) 2 ; R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted C, to C 6 alkyl, -COH, -CO(C, to C 4 alkyl) or-CO(C, to C 4 alkoxy); R 4 is H, halogen, N0 2 , d to C 3 alkyl, substituted Ci to C 3 alkyl; X 1 is N or CX 2 , X 2 is halogen, CN, alkoxy, or N0 2 , G, is O, NR 7 , or CR 7 Rs G 2 is CO or CR 7 Ru; provided that when Gi is O, G 2 is CR 7 Rs, and Gi and G 2 cannot both be CR 7 Rs; wherein R 7 and R« are independent substituents selected from H, alkyl, substituted alkyl, aryl, substituted aryl, heterocychc, or substituted heterocychc; or pharmaceutically acceptable salt thereof 6. A method of Claim 1 in which the antiprogestin compound is 6-(3- CUoro-phenyl)-2,4,4-trimethyl-2-trifluoromethyl-l,4-dihydro-2H-benzo[d][l,3] oxazine or a pharmaceutically acceptable salt thereof. 7. A method of Claim 1 in which the antiprogestin compound is 6-(3- Chloro-phenyl)-2,2,4,4-tetramethyl- 1 ,4-dihydro-2H-benzo [d] [ 1 ,3] oxazine or a pharmaceuticaUy acceptable salt thereof. 8. A method of Claim 1 in which the antiprogestin compound is 6-(3- Nitro-phenyl)-2,2,4,-trimethyl- 1 ,4-dihydro-2H-benzo [d] [ 1 ,3] oxazine or a pharmaceuticaUy acceptable salt thereof. 9. A method of Claim 1 in which the antiprogestin compound is 4-Amino- 3'-chloro-biphenyl-3-carbonitrile or a pharmaceuticaUy acceptable salt thereof. 10. A method of Claim 1 in which the antiprogestin compound is 6-(3- Chlorophenyl)-4-cyclopropyl-lH-quinazoUn-2-one or a pharmaceutically acceptable salt thereof. 11. A method of Claim 1 in which the antiprogestin compound is 6-(3- Chlorophenyl)-4-cyclopropyl-l-(4-methoxybenzyl)-lH-quinazolin-2-one or a pharmaceutically acceptable salt thereof. 12. A method of Claim 1 in which the antiprogestin compound is 6-(3- Chlorophenyl)-4-cyclopropyl-4-methyl-3 ,4-dihydro- 1 H-quinazolin-2-one or a pharmaceuticaUy acceptable salt thereof. 13. A method of Claim 1 in which the antiprogestin compound is 6-(3- CUorophenyl)-4-cyclopropyl-3,4-dimethyl-3,4-dihydro-lH-quinazoUn-2-one or a pharmaceuticaUy acceptable salt thereof. 14. A method of Claim 1 in which the antiprogestin compound is 6-(3- Chloro-phenyl)-4,4-dimethyl-3,4-dihydro-lH-quinolin-2-one or a pharmaceutically acceptable salt thereof. 15. The method of Claim 1 wherein the progestational agent is selected from the group of levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethindrone, gestodene, norethindrone acetate, norgestimate, osaterone, cyproterone acetate, trimegestone, dienogest, drospirenone, nomegestrol, or (17- deacetyl)norgestimate. 16. A method of Claim 1 which comprises administering to a female of child bearing age consecutively over a 28 day cycle: a) a first phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel; b) a second phase of 3 daUy dosage units of an antiprogestin compound of Claim 1, each daUy dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg; and c) optionaUy, 4 daUy dosage units of an oraUy and pharmaceuticaUy acceptable placebo to be administered on each day of the 28-day cycle following the first phase and second phase. 17. A method of contraception which comprises administering to a female of cmld bearing age over a period of 28 consecutive days: a) a first phase of from 18 to 21 daUy dosage units of a progestostational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg; and b) a second phase of from 1 to 7 daUy dosage units of an antiprogestin of Claim 1 at a daUy dose of from about 2 to 50 mg; and c) optionaUy, an orally and pharmaceuticaUy acceptable placebo for each remaining day of the 28 consecutive days. 18. A method of contraception of Claim 17 which comprises administering to a female of chUd bearing age over a period of 28 consecutive days: a) a first phase of 21 daUy dosage units of a progestostational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg; and b) a second phase of 3 daUy dosage units of an antiprogestin of Claim 1 at a daUy dose of from about 2 to 50 mg; and c) optionaUy, a third phase of 4 daUy dosage units of an oraUy and pharmaceutically acceptable placebo. 19. A method of contraception which comprises administering to a female of child bearing age over a period of 28 consecutive days: a) a first phase of from 18 to 21 daily dosage units containing a progestational agent at a daily dose equal in progestational activity to from about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daUy dose range of from about 10 to about 35 μg b) a second phase of from 1 to 7 daUy dose units, each daUy dose unit containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) optionaUy, a third phase of daUy dosage units of an orally and pharmaceuticaUy acceptable placebo, the total of the daily dosage units being 28. 20. A method of contraception of Claim 19 which comprises administering to a female of child bearing age over a period of 28 consecutive days: a) a first phase of 21 daily dosage units, each daUy dosage unit containing a progestational agent at a daily dose equal in progestational activity to about 35 to about 100 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of 3 daily dose, each daUy dose unit containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg; and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) optionaUy, a third phase of 4 daily dosage units of an orally and pharmaceuticaUy acceptable placebo. 21. A pharmaceuticaUy useful kit adapted for daily oral administration which comprises: a) a first phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel; b) a second phase of from 1 to 11 daily dosage units of an antiprogestin compound of Claim 1, each daily dosage unit containing an antiprogestin compound at a daUy dosage of from about 2 to 50 mg; and c) a third phase of daUy dosage units of an orally and pharmaceuticaUy acceptable placebo; wherein the total number of the daily dosage units in the first phase, second phase and third phase equals 28. 22. A pharmaceutically useful kit adapted for daily oral administration of Claim 21 which comprises: a) a first phase of 21 daUy dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel; b) a second phase of 3 daUy dosage units of an antiprogestin compound of Claim 1, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg; and c) a third phase of 4 daily dosage units of an orally and pharmaceuticaUy acceptable placebo. 23 A pharmaceutically useful kit adapted for dady oral administration which compnses a) a first phase of from 18 to 21 dady dosage units of a progestostational agent equal m progestational activity to about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestm of Claim 1 at a dady dose of from about 2 to 50 mg, and c) a third phase of from 0 to 9 dady dosage units of an orally and pharmaceuticaUy acceptable placebo, wherem the total number of the daily dosage units in the first phase, second phase and third phase equals 28 24 A pharmaceutically useful kit adapted for daily oral administration of Claim 23 which compnses a) a first phase of 21 dady dosage units of a progestostational agent equal m progestational activity to about 35 to about 150 μg levonorgestrel and ethmyl estradiol at a dady dose range of from about 10 to about 35 μg, and b) a second phase of three daily dosage units of an antiprogestm of Claim 1 admimstered at a dady dose of from about 2 to 50 mg, and c) a third phase of 4 daily dosage units of an orally and pharmaceutically acceptable placebo 25 A pharmaceuticaUy useful kit adapted for daily oral administration which compnses a) a first phase of from 18 to 21 daily dosage units, each dady dosage unit compnsmg a progestational agent at a daily dose equal m progestational activity to from about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of from 1 to 7 daily dose units, each dady dose unit containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg; and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) a third phase of from 0 to 9 dady dosage units of an oraUy and pharmaceuticaUy acceptable placebo; wherein the total number of the daily dosage units in the first phase, second phase and third phase equals 28. 26. A pharmaceutically useful kit adapted for daily oral administration of Claim 25 which comprises: a) a first phase of 21 dady dosage units, each containing a progestational agent of this invention at a dady dose equal in progestational activity to about 35 to about 150 μg levonorgestrel and ethinyl estradiol at a daily dose range of from about 10 to about 35 μg b) a second phase of 3 daily dose units, each dady dose unit containing an antiprogestin of Claim 1 at a concentration of from 2 to 50 mg; and ethinyl estradiol at a concentration of from about 10 to about 35 μg; and c) a third phase of 4 dady dosage units of an orally and pharmaceuticaUy acceptable placebo.

Inventors: GRUBB GARY S, JONES TODD K, TEGLEY CHRISTOPHER M, ZHI LIN, GRUBB, GARY, S., JONES, TODD, K., TEGLEY, CHRISTOPHER, M., ZHI, LIN
Applicants: AMERICAN HOME PROD, GRUBB GARY S, JONES TODD K, LIGAND PHARM INC, MARSCHKE KEITH B, TEGLEY CHRISTOPHER M, ZHI LIN, AMERICAN HOME PRODUCTS CORPORATION, GRUBB, GARY, S., JONES, TODD, K., LIGAND PHARMACEUTICALS, INC., MARSCHKE, KEITH, B., TEGLEY, CHRISTOPHER, M., ZHI, LIN
Application year: 2000
Main classification: A61K45
IPC codes: A61K31, A61K45, A61P15, A61P35, C07D215, C07D239, C07D265